

0001

1 FRIDAY, JANUARY 22, 1999 MORNING SESSION  
2 \*\*\*\*\*  
3 THE COURT: WE'RE BACK ON THE RECORD. THE  
4 RECORD SHOULD REFLECT THAT WE HAVE COMPLETED THE READING.  
5 WHAT IS OUR NEXT ORDER OF BUSINESS?  
6 MS. CHABER: AT THIS TIME, YOUR HONOR, THE  
7 PLAINTIFF WOULD CALL TO THE STAND DR. ALLAN SMITH.  
8 THE COURT: ARE WE GOING TO BE USING THE  
9 SCREEN?  
10 MS. CHABER: NO.  
11 THE COURT: IF NOT, COULD WE JUST TAKE IT DOWN.  
12 TESTIMONY OF  
13 ALLAN SMITH, M.D.,  
14 A WITNESS CALLED ON BEHALF OF THE PLAINTIFF, HAVING BEEN  
15 DULY SWORN, TESTIFIED AS FOLLOWS: WITNESS SWORN.  
16 THE CLERK: PLEASE STATE YOUR NAME.  
17 THE WITNESS: ALLAN SMITH.  
18 THE CLERK: PLEASE SPELL YOUR LAST NAME.  
19 THE WITNESS: S-M-I-T-H.  
20 THE CLERK: IS ALLAN WITH TWO L'S?  
21 THE WITNESS: YES, A-L-L-A-N.  
22 THE CLERK: THANK YOU. PLEASE TAKE THE STAND.  
23  
24 DIRECT EXAMINATION  
25 BY MS. CHABER: Q. DR. SMITH, COULD YOU TELL  
26 THE JURY WHAT YOU DO.  
27 A. I'M A PROFESSOR OF EPIDEMIOLOGY AT THE UNIVERSITY  
28 OF CALIFORNIA BERKELEY.

JUDITH ANN OSSA, CSR NO. 2310

0002

1 Q. AND ARE YOU A MEDICAL DOCTOR AS WELL?  
2 A. YES.  
3 Q. ARE YOU LICENSED TO PRACTICE IN CALIFORNIA?  
4 A. NO, I DON'T TREAT PATIENTS. I DO RESEARCH AND  
5 TEACHING, SO I DON'T HAVE A LICENSE ANY LONGER TO PRACTICE  
6 MEDICINE ANYWHERE IN THE WORLD.  
7 Q. CAN YOU TELL US WHAT A PROFESSOR OF EPIDEMIOLOGY  
8 DOES.  
9 A. WELL, PART OF MY WORK IS TEACHING, TEACHING  
10 GRADUATE STUDENTS AT THE UNIVERSITY OF CALIFORNIA. PART IS  
11 DOING RESEARCH, INVESTIGATIONS WHERE, IN EPIDEMIOLOGICAL  
12 RESEARCH, WE TRY TO WORK OUT THE CAUSES OF DISEASES IN  
13 HUMANS AND HOW TO PREVENT DISEASES OCCURRING.  
14 Q. CAN YOU GIVE US A BIT OF YOUR BACKGROUND IN TERMS  
15 OF YOUR EDUCATIONAL HISTORY.  
16 A. YES. I WAS BORN IN NEW ZEALAND AND MY EDUCATION  
17 WAS IN NEW ZEALAND. I FIRST STUDIED MATHEMATICS AND  
18 CHEMISTRY. THEN I WENT TO MEDICAL SCHOOL AND COMPLETED  
19 THAT, WORKED IN A HOSPITAL FOR ONE YEAR, AND THEN DECIDED I  
20 WANTED TO GO FULL TIME INTO EPIDEMIOLOGY.  
21 SO I THEN TRAINED IN EPIDEMIOLOGY AND COMPLETED A  
22 PH.D. ALSO IN NEW ZEALAND. I COMPLETED THAT IN 1975.  
23 Q. AND CAN YOU GIVE US A BRIEF HISTORY OF YOUR WORK  
24 EXPERIENCES THAT CORRESPOND TO GET US TO WHERE WE ARE  
25 TODAY.  
26 A. YES. I WAS THEN AWARDED A RESEARCH SCHOLARSHIP  
27 THAT TOOK ME TO THE UNIVERSITY OF NORTH CAROLINA IN CHAPEL  
28 HILL. AND THEN, AFTER A YEAR, I WAS APPOINTED TO THE

JUDITH ANN OSSA, CSR NO. 2310

0003

1 FACULTY THERE AS AN ASSISTANT PROFESSOR, AND TAUGHT IN THE  
2 SCHOOL OF PUBLIC HEALTH OF THE UNIVERSITY OF NORTH CAROLINA

3 IN CHAPEL HILL.

4 AND THEN I RETURNED TO NEW ZEALAND AND TAUGHT IN  
5 A MEDICAL SCHOOL FOR FIVE YEARS, UP UNTIL 1983. AND THAT'S  
6 WHEN I CAME TO BERKELEY, 15 YEARS AGO.

7 Q. NOW, YOU INDICATED THAT SOME OF WHAT YOU DO IS  
8 TEACHING AND SOME OF WHAT YOU DO IS RESEARCH?

9 A. YES. THEY ARE INTERMINGLED, OF COURSE, AND PART  
10 OF MY TEACHING RELATES TO RESEARCH AND SOME OF MY STUDENTS,  
11 OF COURSE, ARE RESEARCH STUDENTS. SO THERE'S OVERLAP THERE.

12 Q. AND OVER THE YEARS, WHAT HAVE BEEN AREAS THAT YOU  
13 HAVE BEEN INVOLVED IN IN YOUR RESEARCH?

14 A. IT HAS ENDED UP FOCUSING OVER MOST OF MY CAREER  
15 ON THE EFFECTS OF VARIOUS CHEMICAL SUBSTANCES IN CAUSING  
16 HUMAN DISEASE, MAINLY CANCER, BUT NOT ONLY.

17 I'VE ALSO DONE STUDIES THAT RELATE TO OTHER  
18 EFFECTS OF, FOR EXAMPLE, ON REPRODUCTION, ON RESPIRATORY  
19 DISEASE.

20 BUT MOST OF MY RESEARCH HAS FOCUSED ON CAUSES OF  
21 CANCERS AND, AGAIN, HOW TO PREVENT THEM FROM OCCURRING.

22 Q. NOW, HOW DOES EPIDEMIOLOGY -- BEFORE I GO ON TO  
23 THAT, HAVE YOU PUBLISHED IN THE FIELD?

24 A. YES.

25 Q. HAVE YOU LECTURED AND GIVEN PRESENTATIONS IN THE  
26 FIELD?

27 A. YES.

28 Q. AND ARE YOU PART OF ANY CANCER GROUPS OR PANELS  
JUDITH ANN OSSA, CSR NO. 2310

0004

1 OR INVESTIGATIONS?

2 A. AT VARIOUS TIMES -- THAT'S RATHER -- THAT COVERS  
3 QUITE A LOT -- I HAVE BEEN ON VARIOUS GOVERNMENT PANELS. I  
4 DO MAJOR PROJECTS FOR THE CALIFORNIA EPA.

5 Q. THAT'S THE ENVIRONMENTAL PROTECTION AGENCY?

6 A. RIGHT. IT USED TO BE THE CALIFORNIA DEPARTMENT  
7 OF HEALTH SERVICES, BUT THAT PART, THEY CHANGED THE NAME TO  
8 THE CALIFORNIA EPA.

9 I DO NATIONAL THINGS THAT RELATE TO THE NATIONAL  
10 CANCER INSTITUTE, THE NATIONAL ACADEMY OF SCIENCES.

11 AND THEN, IN THE INTERNATIONAL AREA, I'VE DONE  
12 WORK THAT RELATES TO THE WORLD HEALTH ORGANIZATION AND THE  
13 INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. BUT THOSE ARE  
14 WHERE I'M AN ADVISER ON A COMMITTEE.

15 BUT A LOT OF WHAT I DO IS ACTUAL RESEARCH,  
16 INVESTIGATIONS.

17 Q. OKAY. AND ARE YOU ACTIVELY INVOLVED AT THIS TIME  
18 IN RESEARCH?

19 A. YES, I AM.

20 Q. AND CAN YOU DESCRIBE SOME OF THAT FOR US.

21 A. THE PROJECTS INCLUDE AN AREA OF ASSESSING  
22 CHEMICAL RISKS IN CAUSING CANCER. AND IN THAT, I CURRENTLY  
23 HAVE WORK THAT RELATES TO DIESEL EXHAUST AS A CAUSE OF LUNG  
24 CANCER, TO SILICA, INHALATION AND SILICOSIS, DISEASE OF THE  
25 LUNGS AND ITS RELATIONSHIP TO LUNG CANCER.

26 I HAVE A PROJECT THAT RELATES TO DIOXIN LEVELS IN  
27 HUMANS AND THE RELATIONSHIP TO VARIOUS CANCER RISKS.

28 BUT THE MAIN PART OF MY CURRENT RESEARCH CONCERNS  
JUDITH ANN OSSA, CSR NO. 2310

0005

1 ARSENIC LEVELS IN DRINKING WATER IN DIFFERENT PARTS OF THE  
2 WORLD. AND IN THAT, I HAVE CURRENTLY A MAJOR STUDY I DIRECT  
3 IN CHILE, ONE IN ARGENTINA, ANOTHER ONE THAT'S IN NEVADA AND  
4 CALIFORNIA, AND ANOTHER ONE THAT'S IN INDIA. AND I'M ALSO  
5 DEVELOPING A PROJECT IN BANGLADESH.

6 Q. COULD YOU JUST GIVE US A BRIEF VERSION OF HOW YOU  
7 GO ABOUT DOING ONE OF THESE STUDIES.

8 A. WELL, FIRST OF ALL, YOU START WITH A CONCEPT OR A  
9 HYPOTHESIS. AND IN THE CASE OF ARSENIC PROJECTS, ONE AREA  
10 WAS, FOR EXAMPLE, DID ARSENIC INGESTION CAUSE BLADDER  
11 CANCER?

12 AND THEN WE GO ABOUT WORKING OUT HOW TO GET  
13 FUNDING TO DO CERTAIN RESEARCH. AND PART OF THAT, WE HAVE  
14 TO FIND PEOPLE WHO ARE HIGHLY EXPOSED. SO THERE IS QUITE A  
15 LONG PERIOD THERE WHERE WE'RE DESIGNING STUDIES, FINDING  
16 POPULATIONS WHO ARE EXPOSED IN THE WORLD AT HIGH LEVELS,  
17 RAISING FUNDS.

18 AND THEN WE ACTUALLY START THE STUDIES. AND THEY  
19 CAN BE OF SEVERAL TYPES. IN SOME STUDIES, WE START WITH  
20 PATIENTS WHO ALREADY HAVE CANCER, AND IN THAT INSTANCE, WE,  
21 IN ARGENTINA, FOR EXAMPLE, WENT TO AN AREA WHERE 34 AREAS  
22 HAD HIGH ARSENIC IN THE WATER AND STARTED IDENTIFYING THE  
23 BLADDER CANCER PATIENTS.

24 AND FOR EACH ONE, WE GOT THE BLADDER TUMOR BIOPSY  
25 FROM OUR PATHOLOGIST WORKING ON THE PROJECT. EACH PATIENT  
26 WAS INTERVIEWED IN DETAIL ABOUT ALL THE HOMES LIVED IN,  
27 WHERE THEY GOT THE WATER.

28 AND THEN I HAVE ANOTHER GROUP WHO GETS WATER  
JUDITH ANN OSSA, CSR NO. 2310

0006

1 SAMPLES FROM THE WATER, PREVIOUS WELLS THEY DRANK FROM,  
2 RIGHT THROUGH THE LAST 30 TO 40 YEARS.

3 AND WE ALSO GETS CELLS FROM THE MOUTH TO LOOK AT  
4 GENES THAT MIGHT RELATE TO SUSCEPTIBILITY. THERE IS A LOT  
5 OF DETAILS. I DON'T WANT TO GO ON AT GREAT LENGTH. THEY  
6 ARE QUITE COMPLICATED STUDIES.

7 BUT THE INTENT OF THEM IN THAT INSTANCE IS: DOES  
8 ARSENIC CAUSE BLADDER CANCER? IF IT DOES, AT WHAT LEVELS?  
9 WHAT'S THE DOSE? WHAT MIGHT MAKE SOME PEOPLE MORE  
10 SUSCEPTIBLE THAN OTHERS?

11 AND ULTIMATELY, THEY ARE FUNDED BECAUSE THEY  
12 RELATE TO THINGS LIKE DRINKING WATER STANDARDS, WHAT LEVEL  
13 SHOULD WE ALLOW TO HAVE ARSENIC IN DRINKING WATER.

14 Q. HAVE YOU DONE WORK ON ASBESTOS?

15 A. YES. I HAVE NOT AN EXTENSIVE FOCUS OF RESEARCH,  
16 BUT I HAVE DONE STUDIES AND HAVE PUBLICATIONS THAT RELATE TO  
17 ASBESTOS, INCLUDING THE WAY ASBESTOS AND SMOKING MAY ACT  
18 JOINTLY IN CAUSING LUNG CANCER, THE EVIDENCE THAT DIFFERENT  
19 TYPES OF ASBESTOS MIGHT CAUSE A CANCER OF THE LINING OF THE  
20 LUNG. THOSE ARE A COUPLE OF AREAS.

21 Q. WE JUST WERE READING A DEPOSITION AND THE WORD  
22 "SYNERGISTICALLY" CAME UP IN RELATION TWO COMPOUNDS.

23 CAN YOU COMPLAIN WHAT "SYNERGISTICALLY" MEANS?

24 A. YES. IT'S WHEN TWO AGENTS, LIKE TWO CHEMICALS,  
25 ACT JOINTLY IN CAUSING CANCER IN A WAY THAT THEY ARE  
26 ENHANCING EACH OTHER'S IMPACT. SO THAT THOSE PEOPLE WHO  
27 HAVE BOTH EXPOSURES ARE MUCH WORSE OFF THAN YOU'D EXPECT,  
28 JUST AS ADDING THE RISKS.

JUDITH ANN OSSA, CSR NO. 2310

0007

1 AND IN ONE OF OUR CURRENT PROJECTS, FOR EXAMPLE,  
2 THERE'S ONE ON LUNG CANCER WHERE WE'RE LOOKING AT THE  
3 SYNERGY BETWEEN ARSENIC AND CIGARETTE SMOKING IN CAUSING  
4 LUNG CANCER.

5 WHAT WE'RE LOOKING FOR IS WHETHER OR NOT, IF YOU  
6 CONSIDER THE RISKS FROM ARSENIC AND THEN SEPARATELY CONSIDER  
7 THE RISKS FROM SMOKING, WHETHER THE SMOKERS WHO HAVE HIGH  
8 LEVELS OF ARSENIC IN THE LUNG HAVE RISKS WAY BEYOND WHAT

9 YOU'D EXPECT, JUST GIVEN THE SEPARATE EFFECTS THAT INDEED  
10 WE'RE FINDING.  
11 WE HAVE ALREADY PUBLISHED ONE PIECE OF EVIDENCE  
12 ON THAT, AND CURRENT STUDIES ARE SHOWING THAT AS WELL.  
13 Q. HOW DOES EPIDEMIOLOGY DETERMINE THE CAUSE OF  
14 HUMAN CANCER?  
15 A. WELL, OBVIOUSLY, IT'S BASED ON SCIENTIFIC  
16 STUDIES. AND THEN WE HAVE A SERIES OF CRITERIA THAT WE USE  
17 TO ASSESS THE HUMAN EVIDENCE THAT WE WORK THROUGH.  
18 AND I DON'T KNOW IF IT WOULD HELP JUST TO LIST  
19 THEM UP THERE.  
20 Q. WHAT'S THE CRITERIA?  
21 A. THESE ARE WHAT WE CALL CRITERIA FOR CAUSAL  
22 INFERENCE (WRITING ON BOARD).  
23 AND WE AS EPIDEMIOLOGISTS TEND TO LIST THEM  
24 SLIGHTLY DIFFERENTLY, BUT THEY ALL RELATE TO CERTAIN  
25 FUNDAMENTAL CONCEPTS. AND I'LL JUST LIST THEM THE WAY I  
26 USUALLY DO IT IN TEACHING.  
27 THE FIRST ONE IS, WE CONSIDER WHETHER OR NOT  
28 STUDIES MIGHT JUST BE PRODUCING CHANCE FINDINGS.  
JUDITH ANN OSSA, CSR NO. 2310

0008

1 Q. WHAT DOES THAT MEAN?  
2 A. WE KNOW THAT NUMBERS FLUCTUATE. SOMETIMES WE'LL  
3 FIND A LITTLE HIGHER RATE THAN ANOTHER, JUST THE RANDOM PLAY  
4 OF NUMBERS. SO WE LOOK AT THAT AND EXAMINE IT AND WANT TO  
5 DISMISS IT, JUST THE EXPLANATION OF WHAT WE'RE FINDING.  
6 Q. WHAT'S THE NEXT ONE?  
7 A. THE SECOND ONE IS WHETHER OR NOT BIAS IS  
8 OCCURRING.  
9 Q. WHAT IS "BIAS"?  
10 MR. BARRON: MAY I JUST INTERRUPT FOR A SECOND.  
11 IS THIS CUMULATIVE TO WHAT WE HAVE ALREADY HAD?  
12 THE COURT: SOME OF IT IS. I DON'T WANT TO GO  
13 OVER MATERIAL THAT WE HAVE ALREADY GONE OVER, SO LET ME JUST  
14 CAUTION YOU, LET'S NOT DO THAT. SOME OF THESE THINGS WE'VE  
15 ALREADY COVERED. I DON'T WANT TO GO OVER THEM TWICE.  
16 LET ME LEAVE IT TO YOUR JUDGMENT TO AVOID DOING  
17 THAT. AND IF THE DEFENDANT'S COUNSEL THINKS THAT IS WHAT'S  
18 HAPPENING, YOU MAKE YOUR OBJECTION. MY RULING IS GOING TO  
19 BE THAT WE DON'T GO OVER THINGS TWICE.  
20 MS. CHABER: RIGHT.  
21 AT THIS POINT, YOUR HONOR, WE'RE GOING TO JUST DO  
22 THIS AS BACKGROUND FOR THE NEXT THING.  
23 THE COURT: I'M NOT GOING INTO BACKGROUND  
24 TWICE. IF WE HAVE HAD THESE CONCEPTS EXPLAINED TO THE JURY  
25 ONCE, WE'RE NOT GOING TO DO IT A SECOND TIME. SO IF YOU ASK  
26 THE QUESTION, YOU ARE REPRESENTING TO US THAT WE HAVEN'T HAD  
27 IT BEFORE, BECAUSE OTHERWISE, I'M GOING TO SUSTAIN THE  
28 OBJECTION. I DON'T WANT TO GO OVER MATERIAL TWICE.  
JUDITH ANN OSSA, CSR NO. 2310

0009

1 MS. CHABER: ALL RIGHT.  
2 THE COURT: I'M SURE THE JURY RECALLS WHAT THEY  
3 HEARD.  
4 MS. CHABER: Q. WHAT DO YOU MEAN BY "BIAS"?  
5 A. I MEAN THAT, SINCE WE CAN'T DO EXPERIMENTS ON  
6 PEOPLE, WE DO STUDIES OF WHAT WE REFER TO AS FREE-LIVING  
7 PEOPLE, THAT PEOPLE MAY DIFFER. AND SINCE THEY DIFFER, YOU  
8 MIGHT GET FINDINGS OF INCREASED RISK THAT DON'T RELATE TO  
9 THE CAUSE YOU'RE LOOKING AT. IT'S SOMETHING ELSE.  
10 THAT'S ONE TYPE OF BIAS. WE CAN LIST ABOUT 100  
11 IN THE EPIDEMIOLOGY. THAT'S ONE TYPE OF CONFOUNDING.

12 ANOTHER TYPE IS MISCLASSIFICATION BIAS, WHERE  
13 THERE'S ERRORS IN DIAGNOSIS OR ERRORS IN EXPOSURE. AND WE  
14 CONSIDER WHETHER OR NOT THIS FINDING THAT WE COME UP WITH IN  
15 OUR STUDIES MIGHT JUST BE A CONSEQUENCE OF SOME TYPE OF  
16 BIAS.

17 Q. OKAY. AND WHAT ELSE DO YOU CONSIDER?

18 A. THE THIRD ONE IS CONSISTENCY. IN EPIDEMIOLOGIC  
19 STUDIES, WE LIKE TO SEE FINDINGS BY DIFFERENT SCIENTISTS IN  
20 DIFFERENT POPULATIONS AND FINDINGS NOT EXACTLY THE SAME, BUT  
21 GENERALLY A PATTERN THAT SUPPORTS CAUSE OCCURRING.

22 Q. OKAY. WHAT'S NEXT?

23 A. THEN WE LOOK AT STRENGTH OF ASSOCIATION.

24 Q. MEANING?

25 A. HERE, WE'RE REFERRING TO HOW BIG ARE THE RISKS IN  
26 A GROUP? HOW STRONG IS THE FINDING? IF THE POPULATION HAS  
27 A TENFOLD RISK OF A DISEASE, FOR EXAMPLE, IT'S VERY STRONG  
28 AND SPEAKS STRONGLY FOR A CAUSAL ASSOCIATION.

JUDITH ANN OSSA, CSR NO. 2310

0010

1 NONE OF THESE ON THEIR OWN PROVE IT, BUT IF THE  
2 ASSOCIATION IS RATHER SMALLER, LET'S SAY 50 PERCENT INCREASE  
3 IN RISK OR RELATIVE RISK, 1.5, THAT IS HARDER TO PROVE  
4 CAUSATION.

5 MR. BARRON: AGAIN, YOUR HONOR, I DO HAVE TO  
6 NOTE, I BELIEVE WE HAVE GONE OVER THIS AT SOME LENGTH.

7 THE COURT: I DO TOO. I DO TOO.

8 I'M GOING TO TELL YOU ONE MORE TIME, MS. CHABER,  
9 LET'S NOT GO OVER MATERIAL. PLEASE RESPECT THE COURT'S  
10 RULING.

11 MS. CHABER: YES, YOUR HONOR.

12 Q. WITH RESPECT TO MS. HENLEY, DID YOU REVIEW  
13 MATERIALS WITH RESPECT TO WHETHER OR NOT THE CRITERIA FOR  
14 CAUSAL INFERENCE HAS BEEN MET IN MS. HENLEY'S CASE?

15 MR. BARRON: OBJECTION, YOUR HONOR. THE LACK OF  
16 FOUNDATION. IMPROPER OPINION AT THIS STAGE.

17 THE COURT: SUSTAINED.

18 MR. BARRON: AND ALSO, VAGUE AND AMBIGUOUS.

19 THE COURT: SUSTAINED.

20 MS. CHABER: Q. DR. SMITH, DO YOU DO ANALYSIS  
21 OF EPIDEMIOLOGY ONLY AS TO GROUPS OF PEOPLE OR CAN IT BE  
22 APPLIED TO INDIVIDUALS?

23 A. THE INTENT OF EPIDEMIOLOGY IS TO STUDY GROUPS SO  
24 THAT WE CAN REACH VALID SCIENTIFIC INFERENCE THAT THEN CAN  
25 BE APPLIED TO DECISION-MAKING, BOTH ABOUT GROUPS AND ABOUT  
26 INDIVIDUALS.

27 Q. AND HAVE YOU DONE AN ANALYSIS OF THAT TYPE WITH  
28 RESPECT TO MS. HENLEY?

JUDITH ANN OSSA, CSR NO. 2310

0011

1 A. YES.

2 Q. AND CAN YOU TELL US, FIRST OF ALL, WHAT DID YOU  
3 DO TO PREPARE FOR THAT ANALYSIS?

4 A. WELL, I READ SOME OF THE MATERIAL BRIEFLY. I WAS  
5 SENT A VARIETY OF DEPOSITIONS. I READ THEM.

6 AND THEN I PONDERED FOR A LONG TIME THAT SINCE  
7 THE EVIDENCE TO ME WAS SO UTTERLY CLEAR, HOW TO EXPLAIN TO  
8 THE JURY THAT THE EVIDENCE ON CAUSATION, IT WAS SO UTTERLY  
9 CLEAR FROM A SCIENTIFIC STANDPOINT.

10 Q. LET ME --

11 MR. BARRON: YOUR HONOR, EXCUSE ME. I'M GOING  
12 TO MOVE TO STRIKE THE LAST PART OF THE ANSWER AS  
13 NONRESPONSIVE. I THINK IT'S WITHOUT FOUNDATION OF WHAT HE  
14 DID.

15 THE COURT: I WILL SUSTAIN AND STRIKE THE LAST  
16 ANSWER.  
17 MS. CHABER: Q. SO HOW DID YOU GO ABOUT  
18 MAKING --  
19 THE COURT: I WILL LEAVE IN THE PORTION OF THE  
20 ANSWER THAT SAYS, "I READ SOME OF THE MATERIAL BRIEFLY. I  
21 WAS SENT A VARIETY OF DEPOSITIONS. I READ THEM."  
22 I WILL LEAVE THAT PORTION IN AND STRIKE THE  
23 BALANCE.  
24 MS. CHABER: RIGHT. OKAY.  
25 Q. AND THEN, HOW DID YOU GO ABOUT MAKING YOUR  
26 ANALYSIS?  
27 A. IT WAS ULTIMATELY SIMPLE. IT WAS SO OBVIOUS, I  
28 SPENT MOST OF THE TIME THINKING ABOUT HOW TO PRESENT IT.

JUDITH ANN OSSA, CSR NO. 2310

0012

1 Q. WHAT WAS OBVIOUS?  
2 A. MAYBE I COULD PUT THAT UP.  
3 Q. WHAT WERE THE FACTORS THAT YOU CONSIDERED, IN  
4 OTHER WORDS?  
5 A. CAN I MARK THIS AS "INCOMPLETE"?  
6 Q. THERE'S A NUMBER 5 ON THAT; CORRECT?  
7 A. 5, 6 AND 7.  
8 Q. WE'LL JUST GO TO THE NEXT PAGE.  
9 A. THERE ARE SOME KEY THINGS. THERE ARE SOME KEY  
10 THINGS. (WRITING ON BOARD)  
11 "THE PATIENT HAS LUNG CANCER (OR MOST  
12 PROBABLY,)" THE WAY I SAW IT.  
13 Q. AND WHAT DID YOU DO TO REACH THAT CONCLUSION?  
14 A. WELL, I NOTED THAT THERE WAS A CLINICAL HISTORY.  
15 CLINICIANS HAD EXAMINED HER. THERE WAS A PATHOLOGY REPORT  
16 AND THE EVIDENCE WAS THAT IT WAS LUNG CANCER.  
17 NOW, I'M NOT A PATHOLOGIST, I'M NOT A CLINICIAN,  
18 BUT I DO STUDIES WHERE I LOOK AT INFORMATION LIKE THAT.  
19 WHEN I SEE INFORMATION LIKE THAT, IN MY JUDGMENT, IT'S MOST  
20 PROBABLY A LUNG CANCER.  
21 OBVIOUSLY, I'M NOT DIAGNOSING MYSELF THE  
22 PATIENT. THIS IS THE WAY THE EVIDENCE SEEMED TO ME AS AN  
23 EPIDEMIOLOGIST.  
24 Q. AND THOSE ARE EVALUATIONS AND CONSIDERATIONS THAT  
25 YOU HAVE TO MAKE AS AN EPIDEMIOLOGIST IN ORDER TO KNOW WHERE  
26 TO CLASSIFY A RESULT?  
27 A. YES. EVERY PATIENT IN OUR STUDY, SOMETIMES WE  
28 JUST HAVE DEATH CERTIFICATE INFORMATION ABOUT THE

JUDITH ANN OSSA, CSR NO. 2310

0013

1 DIAGNOSIS. SOMETIMES WE HAVE THAT PLUS THE MEDICAL  
2 RECORDS. AND SOMETIMES -- IT'S IN THE STUDY I REFERRED  
3 TO -- WE ALSO GET A PATHOLOGY BIOPSY REPORT. AND SOMETIMES  
4 WE ACTUALLY THEN GET THE BIOPSY ITSELF.  
5 SO IT VARIES. BUT IN EVERY STUDY, I HAVE TO MAKE  
6 A DECISION ABOUT WHAT ARE THE CRITERIA THAT WE'LL USE FOR  
7 DIAGNOSIS FOR THE PATIENT TO BE IN THE STUDY.  
8 Q. WHAT WAS THE NEXT FACTOR YOU CONSIDERED?  
9 A. NO. 2. "THE PATIENT SMOKED FOR MANY YEARS."  
10 Q. WHY IS THAT SIGNIFICANT?  
11 A. THE OVERWHELMING EVIDENCE IS THAT THE LARGE  
12 MAJORITY OF LUNG CANCERS ARE CAUSED BY SMOKING.  
13 Q. OKAY.  
14 A. SO BASED ON THIS, NO. 3 IS: "IF IT WERE A LUNG  
15 CANCER, SMOKING CAUSED IT."  
16 AND 4: "IF IT WERE MOST PROBABLY A LUNG CANCER,  
17 SMOKING MOST PROBABLY CAUSED IT."

18 Q. NOW, CAN YOU EXPLAIN THE DIFFERENCE BETWEEN 3 AND  
19 4?  
20 A. YES. SOMETIMES, AT THE END AT THE INDIVIDUAL  
21 LEVEL, THERE'S NOT ABSOLUTE CERTAINTY ON A DIAGNOSIS.  
22 IN THIS INSTANCE, I'D SAY, "WELL, IF IT'S A LUNG  
23 CANCER, NO QUESTION. MOST PROBABLY, ALMOST CERTAINLY  
24 SMOKING CAUSED IT, IF IT'S MOST PROBABLY A LUNG CANCER."  
25 BUT THERE'S STILL SOME DOUBT, AND THEN IT COMES  
26 TO THIS STATEMENT (INDICATING), THAT IF IT'S MOST PROBABLY A  
27 LUNG CANCER, IT'S MOST PROBABLY THAT SMOKING CAUSED IT.  
28 SO IT LINKS DIRECTLY BACK TO WHETHER IT'S MOST  
JUDITH ANN OSSA, CSR NO. 2310

0014

1 ABSOLUTELY A LUNG CANCER OR MOST PROBABLY A LUNG CANCER.  
2 Q. OKAY. IS THAT THE END OF THE FACTORS THAT GET  
3 CONSIDERED AS A BROAD TOPIC?  
4 WE CAN TALK ABOUT THEM SPECIFICALLY.  
5 A. YES. THERE'S NOTHING TO ME TECHNICALLY MORE THAN  
6 THESE KEY POINTS, AND IT'S VERY OBVIOUS. SO ALTHOUGH ONE  
7 COULD TALK FOR TWO HOURS ABOUT ALL THE BASES OF ALL THESE  
8 REASONINGS, THAT'S IT. IT'S VERY SIMPLE.  
9 Q. WELL, I PROMISED THE COURT I WOULDN'T DO THAT.  
10 I WANT TO ASK YOU WHETHER YOU TOOK INTO ACCOUNT  
11 BIAS IN ANALYZING WHETHER OR NOT SMOKING CAUSED OR WAS THE  
12 MOST PROBABLE CAUSE OF MS. HENLEY'S CANCER?  
13 A. I DID.  
14 Q. AND TELL US HOW THAT AFFECTED YOUR  
15 DETERMINATION.  
16 A. IT'S NOT RELEVANT AT ALL.  
17 Q. WHY NOT?  
18 A. THE RELATIONSHIP BETWEEN SMOKING AND LUNG CANCER  
19 IS VERY STRONG. IT'S BEEN CONSISTENTLY SHOWN FROM COUNTRY  
20 TO COUNTRY WORLDWIDE.  
21 WHEN WE HAVE RISKS FOR A CANCER THAT IS AS STRONG  
22 AS THAT, THAT ARE SHOWN CONSISTENTLY, THE IDEA THAT IN TRUTH  
23 THERE'S ANOTHER CAUSE BECOMES RIDICULOUS, AND HAS BEEN  
24 RIDICULOUS FOR MANY YEARS.  
25 Q. NOW, LET ME ASK YOU --  
26 A. IT DOESN'T -- CAN I JUST MAYBE ADD TO THAT?  
27 Q. YES.  
28 A. IT DOESN'T MEAN TO SAY THERE MIGHT NOT BE SOME  
JUDITH ANN OSSA, CSR NO. 2310

0015

1 OTHER FACTOR THAT IS JOINTLY INVOLVED. THAT IS POSSIBLE.  
2 SO I DON'T WANT TO BE MISUNDERSTOOD THERE. I'M  
3 NOT SAYING THAT I WOULD AFFIRM THAT IN EVERY LUNG CANCER  
4 THAT SMOKING WAS THE ONLY CAUSE.  
5 BUT CERTAINLY, IT IS A CAUSE, AND THE PREDOMINANT  
6 CAUSE IN THE GENERAL POPULATION OF LUNG CANCERS.  
7 Q. IN ANALYZING THAT, DO YOU TAKE INTO CONSIDERATION  
8 WHETHER OR NOT SOMEONE'S DIET, THE WAY THEY EAT, THE TYPES  
9 OF FOOD THEY EAT, WHETHER OR NOT THAT IS A FACTOR?  
10 A. NO.  
11 Q. WHY NOT?  
12 A. WELL, IT IS TRUE THAT DIET MAY MODIFY RISK. IN  
13 OTHER WORDS, SOME PEOPLE MAY HAVE A GREATER IMPACT OF  
14 SMOKING BECAUSE OF LOW CONSUMPTION OF, SAY, FRUITS AND  
15 VEGETABLES, BUT THAT IN NO WAY MEANS THAT SMOKING DIDN'T  
16 CAUSE IT. THAT JUST MEANS THAT THEIR DIET MAY HAVE MODIFIED  
17 THE RISK.  
18 SO IT'S JUST NOT RELEVANT TO CONSIDERING WHETHER  
19 OR NOT SMOKING WAS INVOLVED IN CAUSATION OF THE LUNG CANCER.  
20 Q. WHAT ABOUT SOMETHING LIKE EXERCISE OR LACK OF

21 EXERCISE?  
22 A. IT'S RIDICULOUS. EXERCISE DOESN'T CAUSE LUNG  
23 CANCER. NOW, ASSOCIATED WITH PEOPLE WHO EXERCISE, YOU OFTEN  
24 FIND BETTER DIETS. IT MAY MODIFY THEIR RISKS, BUT IT IN NO  
25 WAY ALTERS WHETHER OR NOT SMOKING ACTUALLY CAUSES THE LUNG  
26 CANCER.  
27 Q. IS IT TRUE IF THE PERSON DOESN'T EXERCISE AND IS  
28 MORE SEDENTARY?

JUDITH ANN OSSA, CSR NO. 2310

0016

1 A. CORRECT.  
2 Q. YOU MENTIONED YOU WERE STUDYING DIESEL.  
3 DIESEL EMISSIONS, OR WHAT IS IT?  
4 A. WELL, WE WERE STUDYING DIESEL EXHAUST EXPOSURE TO  
5 WORKERS WHO WERE WORKING INSIDE BUILDINGS WHERE THEY ARE  
6 RUNNING DIESEL ENGINES. SO THEY HAD HIGH DIESEL EXHAUST  
7 EXPOSURE IN PAST YEARS.  
8 AND OUR WORK FOR THE CALIFORNIA EPA WAS TO WORK  
9 OUT WHETHER OR NOT THERE WAS EVIDENCE THAT DIESEL EXHAUST  
10 COULD CAUSE LUNG CANCER.  
11 Q. AND CAN IT?  
12 A. WELL, WE THINK SO. IT'S NOWHERE NEAR AS BIG A  
13 RISK AS SMOKING. SO IT'S MUCH HARDER TO BE SURE ABOUT.  
14 THE RISKS ARE ROUND ABOUT 30, 40, 50 PERCENT IN  
15 LUNG CANCER RATES IN THOSE WORKERS.  
16 AND SO MANY STUDIES -- WE PULLED TOGETHER ABOUT  
17 22 STUDIES, AND WE THINK THERE PROBABLY IS A RELATIONSHIP.  
18 WE THINK THERE PROBABLY IS.  
19 Q. DOES THAT DEPEND UPON WHETHER YOUR WORKERS ARE  
20 BEING EXPOSED TO HIGH LEVELS OR DOES THAT THEN APPLY TO, YOU  
21 KNOW, THE GENERAL POPULATION THAT'S WALKING AROUND BREATHING  
22 EXHAUST FUMES?  
23 A. WELL, THE STUDIES ARE OF THE HIGH EXPOSURES. THE  
24 REASON WE WERE FUNDED TO DO THAT WORK WAS THAT THE  
25 CALIFORNIA EPA IS INTERESTED IN REGULATING CITY AIR  
26 POLLUTION.  
27 NOW, WHAT THEY THEN DO IS EXTRAPOLATE DOWN TO THE  
28 MUCH LOWER EXPOSURES IN URBAN AIR FROM THE INFORMATION WITH  
JUDITH ANN OSSA, CSR NO. 2310

0017

1 THESE RELATIVELY HIGH WORKER EXPOSURES.  
2 Q. IS THERE EVIDENCE THAT DIESEL EXHAUST IN THE AIR  
3 THAT WE BREATHE OUTSIDE CAUSES LUNG CANCER?  
4 A. WELL, IT MAY DO IT, BUT IF IT DOES, IT'S NOT THAT  
5 COMMON. WE CAN'T PROVE WHETHER OR NOT IT REALLY DOES.  
6 THE RISK ESTIMATES ARE THAT POSSIBLY ON THE ORDER  
7 OF ONE IN 1,000 PEOPLE MIGHT GET A LUNG CANCER TO WHICH  
8 DIESEL EXHAUST CONTRIBUTED IN INNER URBAN AIR, BUT THAT RISK  
9 IS VERY, VERY LOW COMPARED TO SMOKING AND LUNG CANCER.  
10 IT'S NOT THE SORT OF RISK WE CAN PROVE  
11 SCIENTIFICALLY TO KNOW WHETHER IT IS REAL OR NOT. IT MAY BE  
12 OR MAY NOT BE.  
13 Q. WHAT ABOUT AIR POLLUTION? IF YOU LIVE IN THE  
14 CITY, IS THERE MORE LUNG CANCER THAN IF YOU LIVE IN A RURAL  
15 AREA?  
16 A. WELL, THERE IS SOME HIGHER RATES OF LUNG CANCER  
17 IN URBAN POPULATIONS IN MANY COUNTRIES, BUT THE PREDOMINANT  
18 CAUSE OF THAT IS THE SMOKING RATES STARTED OFF HIGHER IN  
19 URBAN AREAS.  
20 NOW, THERE IS REASON TO BELIEVE THAT MAYBE THERE  
21 ARE SOME RISKS FROM URBAN AIR POLLUTION IN CAUSING SOME LUNG  
22 CANCERS. AGAIN, THE RISKS ARE QUITE LOW.  
23 THE REGULATORS HAVE TO ACT AS IF MAYBE THEY MIGHT



24 BE REAL, BUT IT'S VERY HARD TO PROVE WHETHER THEY ARE OR  
25 NOT.  
26 Q. AND IF AN INDIVIDUAL WAS A CIGARETTE SMOKER AND  
27 ALSO LIVED IN AN URBAN ENVIRONMENT, IS THERE A WAY TO SAY  
28 THAT SMOKING CAUSED THE LUNG CANCER IN THAT INDIVIDUAL OR  
JUDITH ANN OSSA, CSR NO. 2310  
0018  
1 IT'S THE AIR POLLUTION, OR YOU CAN'T MAKE THAT  
2 DETERMINATION?  
3 A. YES, YOU CAN. I MEAN, CERTAINLY IT'S THE SMOKING  
4 THAT CAUSED THE CANCER.  
5 NOW, THERE IS A POSSIBILITY THAT SOME CHEMICALS  
6 CALLED PAH'S THAT ARE ALSO IN URBAN AIR CONTRIBUTED A LITTLE  
7 BIT TO THE DOSE. BUT THE OVERWHELMING DOSE IN SUCH A PERSON  
8 WHO GOT LUNG CANCER WOULD HAVE COME FROM THEIR SMOKING, BUT  
9 THEY DRAW A VERY CLEAR ANSWER.  
10 WHETHER OR NOT A CONTRIBUTION TO THE DOSE THAT  
11 CAUSED IT CAME FROM URBAN AIR WOULD BE A MATTER OF  
12 SCIENTIFIC DEBATE, THEORETICAL SPECULATION IN PART.  
13 BUT, NO, THE SMOKING WOULD BE THE OVERRIDING  
14 CLEAR-CUT DECISION ONE COULD MAKE ABOUT IT.  
15 Q. AND THERE ARE PAH'S PRODUCED WHEN YOU INHALE ON A  
16 CIGARETTE; CORRECT?  
17 A. YES, INDEED, VERY HIGH LEVELS OF DIFFERENT ONES,  
18 ESPECIALLY BENZOPYRENE.  
19 MS. CHABER: DO YOU WANT TO TAKE THE LUNCH  
20 BREAK?  
21 THE COURT: DO YOU WANT TO GO TO LUNCH?  
22 MS. CHABER: YES.  
23 THE COURT: OKAY. JURORS, OVER THE NOON HOUR,  
24 PLEASE CONTINUE TO FOLLOW THE ADMONITION. YOU KNOW IT'S  
25 CRITICAL. WE'LL SEE YOU BACK AT 1:30.  
26 HAVE A GOOD LUNCH. WE'LL SEE YOU AT 1:30.  
27 (LUNCH RECESS TAKEN AT 12:00 NOON)  
28

JUDITH ANN OSSA, CSR NO. 2310

0019  
1 AFTERNOON SESSION 1:35 P.M.  
2 FRIDAY, JANUARY 22, 1999  
3 (THE FOLLOWING PROCEEDINGS WERE HELD IN  
4 THE COURTROOM, IN THE PRESENCE OF THE JURY)  
5 THE COURT: OKAY. GOOD AFTERNOON, EVERYBODY.  
6 WE'RE BACK ON THE RECORD.  
7 YOU MAY PROCEED, MS. CHABER.  
8 MS. CHABER: THANK YOU.  
9  
10 CONTINUED DIRECT EXAMINATION  
11 BY MS. CHABER: Q. BEFORE BE BROKE FOR LUNCH,  
12 WE WERE TALKING ABOUT OTHER THINGS THAT POTENTIALLY COULD  
13 CAUSE LUNG CANCER WHICH MIGHT CONFOUND, I THINK WAS THE WORD  
14 YOU USED, AN ANALYSIS OF WHETHER SMOKING CAUSED A LUNG  
15 CANCER.  
16 A. YES.  
17 Q. WHILE YOU WERE GETTING YOUR PH.D., DID YOU HAVE  
18 TO ANALYZE AND PRESENT INFORMATION ABOUT SMOKING DURING THE  
19 COURSE OF THAT?  
20 A. YES, I DID BOTH. PART OF MY PH.D. WORK WAS  
21 DIRECTLY ON SMOKING AND SOME PERIPHERAL VASCULAR EFFECTS.  
22 AND THE TIMES I GAVE LECTURES IS WHEN I ALREADY  
23 HAD MY M.D. I WAS STUDYING FOR A PH.D.  
24 Q. AND WHAT WERE THE TOPICS THAT YOU WOULD LECTURE  
25 ON?  
26 A. WELL, I REMEMBER THE FIRST LECTURE I GAVE, I

27 THINK, IN MY PROFESSIONAL CAREER WAS ON LUNG CANCER. MY  
28 PROFESSOR ASKED ME IF I WOULD PREPARE A LECTURE ON LUNG  
JUDITH ANN OSSA, CSR NO. 2310

0020

1 CANCER AND THE EVIDENCE RELATING TO SMOKING AND THE CAUSES  
2 OF IT. I THINK IT WAS IN 1972 OR VERY CLOSE TO THAT, 1972.  
3 HE GAVE ME A VOLUME OF MATERIAL THAT HE HAD ON  
4 THE TOPIC AND ON MANY OTHER DIFFERENT TOPICS. HE SAID "HERE  
5 IS A VOLUME OF SMOKING INFORMATION."

6 I STUDIED IT AND GAVE THE LECTURE.

7 Q. AND WHAT TYPES OF THINGS DID YOU ANALYZE IN THAT  
8 LECTURE?

9 A. WELL, I GAVE THE LECTURE ON THE EVIDENCE THAT WAS  
10 VERY CLEAR, THAT SMOKING CAUSED LUNG CANCER, AND THEN  
11 PRESENTED THE VARIOUS ALTERNATIVE THEORIES AND WHAT I  
12 DESCRIBED AS QUAIN'T HYPOTHESES THAT WERE PUT FORWARD TO TRY  
13 AND CONCEAL THE RELATIONSHIP BETWEEN SMOKING AND LUNG  
14 CANCER.

15 Q. AND WHAT WERE THOSE QUAIN'T HYPOTHESES?

16 A. I REMEMBER THREE. THERE WERE OTHERS, I KNOW, BUT  
17 THE THREE THAT CAME TO MIND WHEN I WAS THINKING ABOUT IT,  
18 ONE WAS THAT IT'S NOT THE SMOKING, IT'S THE PERSONALITY TYPE  
19 THAT TAKES UP SMOKING, AND IT'S PERSONALITY OR SOMETHING TO  
20 DO WITH YOUR LOGIC SYSTEM THAT CAUSED THE LUNG CANCER. THAT  
21 WAS PUT FORWARD, THAT PEOPLE WHO SMOKE ARE DIFFERENT IN  
22 THEIR PERSONALITIES AND THAT'S WHY THEY GET LUNG CANCER.

23 ANOTHER ONE WAS THAT THE RISKS AT THAT TIME  
24 APPEARED IN ENGLAND TO BE HIGHER FOR THE SAME CIGARETTE  
25 SMOKING THAN IN THE U.S. IT WAS SUGGESTING THAT'S EVIDENCE  
26 THAT SMOKING DOESN'T CAUSE LUNG CANCER.

27 SUBSEQUENTLY -- THE EVIDENCE WAS NOTED IN ENGLAND  
28 AT THAT TIME THAT APPARENTLY THEY SMOKED RIGHT DOWN TO THE  
JUDITH ANN OSSA, CSR NO. 2310

0021

1 BUTT. THEY COULDN'T AFFORD THE CIGARETTES. IT WAS RIGHT  
2 DOWN TO THE END, WHERE THE LIPS WERE ALMOST BURNING.

3 IN THE U.S., WHERE THEY COULD AFFORD TO PAY  
4 BETTER, THEY PROBABLY DIDN'T SMOKE RIGHT DOWN. THAT WAS THE  
5 PROBABLE EXPLANATION.

6 BUT NEVERTHELESS, IT WAS PUT FORWARD AS AN IDEA.  
7 "WELL, THIS DOESN'T FIT. THEREFORE, SMOKING DOESN'T CAUSE  
8 LUNG CANCER."

9 THE THIRD ONE I REMEMBER VERY DISTINCTLY BECAUSE  
10 I'M NOW WORKING ON ARSENIC. AT THAT TIME, THEY USED  
11 ARSENICAL PESTICIDES ON TOBACCO. AND SO THEY SAID, "WELL,  
12 IT'S THE ARSENIC FROM THE PESTICIDES THAT'S CAUSING THESE  
13 LUNG CANCERS, NOT THE TOBACCO, AND WE'LL JUST STOP USING  
14 ARSENIC PESTICIDES AND THE RISKS WILL GO AWAY."

15 THOSE WERE THREE OF THESE WHAT I'VE DESCRIBED AS  
16 RED HERRING DIVERSION THEORIES THAT WERE PUT FORWARD AT THAT  
17 TIME AGAINST SMOKING CAUSING LUNG CANCER.

18 Q. WERE THESE THEORIES THAT WERE PUT FORWARD IN  
19 NEWSPAPERS AND MAGAZINES?

20 A. WELL, SOME WERE IN NEWSPAPERS. SOME WERE IN  
21 JOURNAL ARTICLES.

22 THE COLLECTIONS MY PROFESSOR HAD ON ALL THESE  
23 TOPICS OF INTEREST CONSISTED OF CUTTINGS FROM VARIOUS  
24 SOURCES, JOURNAL ARTICLES, NEWSPAPERS, MANY OF THEM FROM  
25 NEWSPAPERS REPORTING ON TOBACCO COMPANY STATEMENTS OR THE  
26 TOBACCO INSTITUTE STATEMENTS.

27 Q. AND DO YOU CONTINUE TO USE THE TOPIC OF SMOKING  
28 IN TEACHING EPIDEMIOLOGY AT THE SCHOOL OF PUBLIC HEALTH AT

JUDITH ANN OSSA, CSR NO. 2310

0022

1 BERKELEY?

2 A. I DO.

3 Q. AND HOW DO YOU USE IT?

4 A. WELL, THERE ARE VARIOUS PLACES IT COMES IN.

5 OBVIOUSLY, I DON'T TALK NOW ABOUT THE EVIDENCE OF SMOKING  
6 CAUSING LUNG CANCER. THAT IS OLD STUFF.

7 BUT I DO, IN THE RISK CLASSES, MAKE SURE STUDENTS  
8 APPRECIATE WHAT THESE RISKS ARE, THAT FOR REGULAR SMOKERS,  
9 OF THE ORDER OF TWO OUT OF FIVE SMOKERS WILL DIE FROM  
10 SMOKING.

11 SO THAT WHEN THEY'RE TALKING ABOUT OR THINKING  
12 ABOUT OTHER RISKS, LIKE AIR POLLUTION OR BENZENE, A CHEMICAL  
13 THAT CAUSES LEUKEMIA OR OTHER THINGS THEY'RE CALCULATING,  
14 THEY ARE AWARE OF THE STARK CONTRAST BETWEEN THAT AND THE  
15 RISKS THAT AROSE FROM SMOKING OR DO ARISE FROM SMOKING.

16 ANOTHER AREA IS, IN WORKPLACE STUDIES AND IN  
17 OTHER AREAS WHERE WE'RE LOOKING FOR LUNG CANCER, WE HAVE TO  
18 BE CONCERNED ABOUT SMOKING MIGHT EXPLAIN SOME WORKPLACE  
19 INCREASED RISKS SO IN STUDY DESIGN, WE CONSIDER THAT AND HOW  
20 TO INTERPRET IT.

21 SO THAT IF YOU REACH A CONCLUSION ABOUT A  
22 CHEMICAL IN INDUSTRY MAY BE CAUSING LUNG CANCER, THEY ARE  
23 AWARE OF HOW TO DEAL WITH THIS "CONFOUNDING." SMOKING MAY  
24 BE THE REAL EXPLANATION, IF YOU'RE NOT CAUTIOUS.

25 THE THIRD ONE IS AN AREA WHERE WE DO TEACHING  
26 RESEARCH. THAT IS WHAT I MENTIONED BEFORE. SMOKING AND  
27 OTHER AGENTS MAY ENHANCE ITS EFFECTS OR ACT SYNERGISTICALLY  
28 WITH IT.

JUDITH ANN OSSA, CSR NO. 2310

0023

1 ASBESTOS IS AN EXAMPLE OF THAT, A CLASSIC  
2 EXAMPLE, AND I TEACH ABOUT THAT. WE'RE DOING RESEARCH ON  
3 THAT AND I TEACH ABOUT THAT.

4 Q. NOW, IN TERMS OF QUITTING SMOKING, HAVE YOU  
5 LOOKED AT THE RISKS AND THE REDUCTION IN RISK FROM QUITTING  
6 SMOKING?

7 A. YES.

8 Q. AND CAN YOU TELL US ABOUT THAT.

9 A. YES. THE STUDIES -- I CAN'T REMEMBER EXACTLY  
10 WHEN THE FIRST ONES WERE. MAYBE 20 YEARS AGO WE STARTED  
11 FINDING OR FOLLOWING PEOPLE WHO STOPPED SMOKING COMPARED TO  
12 THOSE WHO CONTINUED. AND THERE HAVE BEEN MANY STUDIES NOW  
13 LIKE THAT, QUITE A FEW, THAT GIVE INFORMATION ABOUT HOW THE  
14 RISKS COMPARE BETWEEN THE CONTINUING SMOKERS AND THOSE THAT  
15 DROP IT.

16 AND IN MY OPINION, THE DIFFERENCE BETWEEN THEM  
17 STARTS AROUND THREE, FOUR, ABOUT FIVE YEARS. I THINK  
18 THERE'S A BEGINNING OF LOWER LUNG CANCER RISK IN THOSE WHO  
19 STOP SMOKING. BY 10 YEARS, IT'S VERY CLEAR. AND 20 YEARS,  
20 IT'S STARTING TO GET COMPARED TO WHAT IT WAS NEARER THAT OF  
21 NONSMOKERS.

22 BUT IT REMAINS CLEARLY ABOVE THAT OF NONSMOKERS,  
23 IN MY VIEW, LOOKING AT STUDIES OVERALL AT 20 YEARS AND 25  
24 YEARS, EVEN AFTER STOPPING. BUT IT'S MUCH CLOSER, OF  
25 COURSE, TO NONSMOKERS THAN IT IS BY THEN TO THE PEOPLE WHO  
26 CONTINUE TO SMOKE.

27 Q. SO YOU KNOW CLEARLY THERE'S A BENEFIT FROM  
28 QUITTING SMOKING, BUT DOES THE PERSON WHO QUIT SMOKING EVER

JUDITH ANN OSSA, CSR NO. 2310

0024

1 GET BACK TO THE LEVEL OF A NONSMOKER?

2 A. WELL, THAT IS NOT CLEAR.

3 NOW, WHAT IS CLEAR WITH HEART DISEASE IS THEY  
4 BENEFIT VERY QUICKLY IN STOPPING SMOKING.

5 MR. BARRON: YOUR HONOR, I THINK THAT IS  
6 NONRESPONSIVE.

7 THE COURT: YES. I THINK YOU'VE ANSWERED THE  
8 QUESTION. I THINK THE QUESTION YOU ASKED DIDN'T HAVE  
9 ANYTHING TO DO WITH THE HEART.

10 DO YOU WANT ME TO STRIKE THE REFERENCE TO THE  
11 HEART AND LEAVE IN THE REST?

12 MR. BARRON: YES, YOUR HONOR.

13 THE COURT: ALL RIGHT. THAT'S WHAT I'M DOING.

14 MS. CHABER: Q. YOU SAID IT'S NOT CLEAR.

15 WHAT DID YOU MEAN BY "IT'S NOT CLEAR"?

16 A. I GUESS I WASN'T CLEAR ON THE QUESTION. JUST ON  
17 LUNG CANCER, DO I UNDERSTAND?

18 Q. I WAS ASKING YOU ABOUT THE RISKS FROM SMOKING.  
19 LET ME CLARIFY.

20 IN ADDITION TO THE RISK FROM SMOKING WITH RESPECT  
21 TO LUNG CANCER, ARE THERE RISKS OF OTHER DISEASES AS WELL?

22 A. YES.

23 Q. AND WHAT DISEASES ARE WE TALKING ABOUT?

24 A. THE CARDIOVASCULAR DISEASES, HEART ATTACKS. SOME  
25 OF THE MAIN ONES ALSO, WHAT WE CALL PERIPHERAL VASCULAR  
26 DISEASE. THE ONE --

27 MR. BARRON: I DON'T MEAN TO INTERRUPT, BUT THIS  
28 IS CUMULATIVE. HAVEN'T WE BEEN THROUGH ALL THIS?

JUDITH ANN OSSA, CSR NO. 2310

0025

1 MS. CHABER: I HAVEN'T DEALT WITH THE QUITTING  
2 ISSUE.

3 THE COURT: DIDN'T YOU ASK OTHER WITNESSES ABOUT  
4 THE RISKS AFTER PERIODS OF TIME WITH RESPECT TO --

5 MS. CHABER: NO. THAT WAS CROSS-EXAMINATION BY  
6 THEM. I DID NOT ASK THAT.

7 THE COURT: ALL RIGHT. IF THAT'S TRUE, YOU CAN  
8 GO AHEAD.

9 MS. CHABER: Q. WITH RESPECT TO THE RISKS FOR  
10 DISEASE FROM SMOKING FROM QUITTING CIGARETTES, DOES THE RISK  
11 TO THE INDIVIDUAL WHO WAS A SMOKER BUT QUIT EVER GET BACK TO  
12 THE LEVEL OF A NONSMOKER?

13 A. WELL, IN MY OPINION, AS FAR AS LUNG CANCER GOES,  
14 IT'S NOT ABSOLUTELY CLEAR. IT IS CLEAR THAT BY ABOUT 30  
15 YEARS, IN MY OPINION, IT'S GETTING PRETTY CLOSE, BUT TO BE  
16 ABSOLUTELY SURE IS VERY HARD.

17 IT'S ALSO MY OPINION THAT 20 YEARS AFTER  
18 STOPPING, THERE'S STILL INCREASED RISKS OF LUNG CANCER. AND  
19 SO I DON'T KNOW IF -- IT'S NOT ABSOLUTELY CLEAR TO ME IF IT  
20 DEFINITELY GETS RIGHT BACK TO NONSMOKERS.

21 THERE IS NO GOOD EVIDENCE IN MY VIEW THAT WOULD  
22 ALLOW ONE TO CONCLUDE THAT, BUT IT DOES GET, AFTER A LONG  
23 PERIOD OF TIME, QUITE CLOSE.

24 Q. AND AFTER 20 YEARS, WHEN YOU SAY IT'S CLOSER BUT  
25 THERE'S STILL A RISK, WHAT TYPE OF MAGNITUDE OF RISK ARE WE  
26 TALKING ABOUT THAT STILL EXISTS TO THE QUIT SMOKER 20 YEARS  
27 OUT?

28 A. IT'S THE ORDER OF A TWOFOLD RISK. SOME STUDIES

JUDITH ANN OSSA, CSR NO. 2310

0026

1 DON'T FIND -- THREEFOLD SOMETIMES. SOME ACTUALLY DON'T FIND  
2 ANY INCREASED RISK. BUT THE OVERALL OR MAJORITY OF STUDIES  
3 AND THE LARGE ONES STILL FIND INCREASED RISK.

4 NOW, IT DOES DEPEND ON HOW MUCH YOU SMOKE A DAY  
5 TO START WITH, AND IN THE MORE-THAN-A-PACK-A-DAY SMOKERS,

6 SOME STUDIES STILL FIND TWO, THREE OR FOURFOLD RISK AFTER 20  
7 YEARS. SOME FIND LESS THAN THAT.

8 Q. AND A TWO, THREE OR FOURFOLD RISK, IS THAT STILL  
9 A VERY SUBSTANTIAL AND SIGNIFICANT RISK?

10 MR. BARRON: OBJECTION, YOUR HONOR. VAGUE AND  
11 AMBIGUOUS.

12 THE COURT: SUSTAINED.

13 MS. CHABER: Q. HOW WOULD YOU DESCRIBE THE  
14 LEVEL OF MAGNITUDE OF RISK THAT THERE IS A TWOFOLD,  
15 THREEFOLD, FOURFOLD RISK TO THE 20-YEAR QUIT SMOKER OF MORE  
16 THAN A PACK A DAY?

17 A. FOURFOLD, THAT'S FAIRLY HIGH. IN CURRENT  
18 CONTINUING SMOKERS, FOR EXAMPLE, THE RISK OF BLADDER CANCER  
19 IS ABOUT TWO TO FOURFOLD. AND I REGARD THAT AS HIGH RISK IN  
20 TERMS OF A CANCER-CAUSING SUBSTANCE.

21 MS. CHABER: THANK YOU. I HAVE NO FURTHER  
22 QUESTIONS.

23 THE COURT: OKAY. MR. BARRON.

24 MR. BARRON: YES. THANK YOU, YOUR HONOR.

25

26 CROSS-EXAMINATION

27 BY MR. BARRON: Q. GOOD AFTERNOON, DOCTOR.

28 A. GOOD AFTERNOON.

JUDITH ANN OSSA, CSR NO. 2310

0027

1 Q. I'LL TAKE A SECOND SO I CAN BE ABLE TO ADDRESS  
2 SOME DOCUMENTS WITH YOU.

3 THE COURT: OH, ACTUALLY, BEFORE YOU START, IF  
4 DR. SMITH IS DONE DOING HIS DRAWINGS -- I THINK THERE ARE  
5 TWO PAGES OF THOSE DRAWINGS UP THERE.

6 MS. CHABER: THERE'S THE FIRST INCOMPLETE PAGE  
7 AND THE SECOND PAGE.

8 THE COURT: LET'S MARK THOSE. IF THERE'S NOT  
9 GOING TO BE ANY MORE DRAWING, LET'S MARK THOSE TWO PAGES AS  
10 PLAINTIFF'S 61 FOR IDENTIFICATION.

11 (DOCUMENT MORE PARTICULARLY  
12 DESCRIBED IN THE INDEX MARKED  
13 FOR IDENTIFICATION PLAINTIFF'S  
14 EXHIBIT # 61)

15 THE COURT: FOR THE RECORD, WAS THAT TWO PAGES,  
16 TATSUO?

17 THE CLERK: I BELIEVE SO.

18 THE COURT: OKAY, THAT'S TWO PAGES.

19 OKAY. MR. BARRON.

20 MR. BARRON: THANK YOU, YOUR HONOR.

21 Q. DOCTOR, AM I CORRECT THAT EPIDEMIOLOGY MEANS  
22 A STATISTICAL STUDY OF HUMAN HEALTH AND DISEASE?

23 A. NO, I WOULDN'T WORD IT THAT WAY. IT INCLUDES  
24 STATISTICS, BUT THAT'S NOT ITS DEFINITION.

25 Q. HAVE YOU SEEN IT DESCRIBED THAT WAY IN SURGEON  
26 GENERAL'S REPORTS?

27 A. I HAVE SEEN REFERENCE TO IT BEING MADE, THAT PART  
28 OF IT, BUT I DON'T RECALL SEEING THAT SPECIFIC PHRASE IN THE  
JUDITH ANN OSSA, CSR NO. 2310

0028

1 SURGEON GENERAL'S REPORTS.

2 Q. DO YOU AGREE THAT ONE OF THE THINGS THAT  
3 EPIDEMIOLOGY DOES IS TO TRY TO LOOK FOR AND DISCOVER  
4 ANYTHING THAT HAS A STATISTICAL RELATIONSHIP WITH DISEASE?

5 A. I WOULDN'T WORD IT THAT WAY, COUNSEL. IT IS PART  
6 OF IT, AND STATISTICS, BUT WHAT WE DO IS TRY WORK OUT THE  
7 CAUSES OF DISEASE IN HUMANS.

8 Q. DON'T YOU HAVE TO START IN YOUR EPIDEMIOLOGICAL

9 WORK BY LOOKING AT STATISTICAL ASSOCIATIONS? DO YOU USE  
10 EPIDEMIOLOGY TO GO OUT AND TRY TO DISCOVER, FOR EXAMPLE, THE  
11 MECHANISM BY WHICH A DISEASE LIKE CANCER IS CAUSED?  
12 A. YES.  
13 Q. YOU'VE DONE THAT?  
14 A. I DO IT ALL THE TIME. WE DO STUDIES WHERE WE GET  
15 TUMORS. WITH MY COLLEAGUES, WE EXAMINE THE DNA PATTERNS,  
16 TRY TO FIND THE MUTATIONS THAT MIGHT RELATE TO CERTAIN  
17 CHEMICALS.  
18 WE ALSO LOOK AT THE ROUTE OF CHEMICALS GETTING TO  
19 DIFFERENT SITES. WE ALSO LOOK AT CHANGES IN CELLS.  
20 FOR EXAMPLE, IN OUR BLADDER CANCER WORK, WE  
21 COLLECT BLADDER CELLS AND LOOK FOR GENETIC CHANGES. IN ALL  
22 THAT WORK, WE'RE TRYING TO WORK OUT THE -- NOT ONLY WHETHER  
23 OR NOT THE AGENT CAUSES THE DISEASE, BUT SOME OF THE  
24 MECHANISMS BY WHICH IT DOES IT.  
25 Q. IN ANY EVENT, AT SOME POINT, WHATEVER YOU LOOK  
26 AT, YOU TRY TO OFFER SOME INFORMATION ABOUT WHETHER  
27 SOMETHING IS A RISK FACTOR FOR SOMETHING ELSE? IN OTHER  
28 WORDS, FOR EXAMPLE, WHETHER AN AGENT OR A COURSE OF CONDUCT  
JUDITH ANN OSSA, CSR NO. 2310

0029

1 IS A RISK FACTOR FOR A PARTICULAR DISEASE, CORRECT?  
2 A. THAT IS PART OF IT, YES, COUNSEL, BUT IT'S NOT  
3 THE KEY PART.  
4 Q. ISN'T THIS HOW YOU DEFINE "RISK FACTOR";  
5 SOMETHING THAT HAS A HIGHER STATISTICAL ASSOCIATION WITH A  
6 DISEASE?  
7 A. NO.  
8 Q. HOW DO YOU DEFINE IT?  
9 A. VARIOUS WAYS. AND IT HAS CHANGED A LITTLE BIT  
10 OVER THE YEARS.  
11 THE RISK FACTOR IS A FACTOR WHICH APPEARS IN A  
12 SERIES OF POPULATIONS TO BE RELATED TO INCREASED RISKS OF A  
13 DISEASE. WE DON'T USE IT JUST AS A FACTOR THAT IN SOME  
14 STUDY FOUND INCREASED RISKS, AND WE ALSO RESERVE IT FOR ONES  
15 WHERE THERE'S EVIDENCE OF A CAUSAL LINK.  
16 THERE IS A TERM THAT WE -- OR SOME OF US USE  
17 CALLED A RISK INDICATOR, WHICH WOULD JUST BE A FACTOR THAT  
18 HAPPENED TO HAVE A STATISTICAL RELATIONSHIP.  
19 BUT THE WORD "RISK FACTOR" WE'RE USING MUCH MORE  
20 IN RELATIONSHIP TO IT LIKELY BEING A CAUSAL FACTOR.  
21 Q. WELL, IF WE TAKE SOMETHING -- LET'S TAKE A  
22 DISEASE LIKE YOU MENTIONED, HEART DISEASE.  
23 YOU WOULD SAY THAT THERE ARE CERTAIN THINGS THAT  
24 ARE ASSOCIATED WITH A HIGHER RISK OF HEART ATTACK; CORRECT?  
25 A. YOU COULD SAY THAT, YES.  
26 Q. BUT YOU WOULDN'T NECESSARILY SAY THAT IN A  
27 PARTICULAR PATIENT'S CASE, JUST BASED ON THE STATISTICAL  
28 RELATIONSHIP, THAT THAT PATIENT DIED OF A HEART ATTACK  
JUDITH ANN OSSA, CSR NO. 2310

0030

1 BECAUSE OF THAT PARTICULAR RISK FACTOR; CORRECT?  
2 A. YOU MIGHT. IT DEPENDS ON THE CIRCUMSTANCES.  
3 THE EVIDENCE, FOR EXAMPLE, THAT HIGH BLOOD  
4 PRESSURE IS RELATED TO HEART ATTACKS, EPIDEMIOLOGY OBVIOUSLY  
5 HAS STUDIES OF PEOPLE.  
6 THE EVIDENCE THAT SMOKING WAS INVOLVED, THE  
7 EVIDENCE THAT CHOLESTEROL MIGHT BE RELATED, COMES FROM  
8 EPIDEMIOLOGICAL STUDIES OF PEOPLE.  
9 SO WHEN I THEN MAKE AN INFERENCE ABOUT ONE  
10 PATIENT WHO HAS A HEART ATTACK AND DIES FROM IT, THE  
11 QUESTION IS WHAT CAUSED THE HEART ATTACK, AND ONE DRAWS FROM

12 THOSE POPULATION STUDIES IN DECIDING THAT, WELL, IT'S  
13 PROBABLE, IN THAT PERSON, CHOLESTEROL, SMOKING, LACK OF  
14 EXERCISE OR WHATEVER WERE INVOLVED IS A CAUSE OF IT.  
15 Q. I'M NOT SURE WE'RE CONNECTING HERE. LET ME JUST  
16 ASK YOU THIS FOR AN EXAMPLE.

17 THERE ARE THINGS THAT WE KNOW ABOUT THAT ARE  
18 APPARENTLY RELATED IN TIME.

19 THAT DOESN'T NECESSARILY MEAN THAT ONE THING  
20 CAUSES THE OTHER; CORRECT?

21 A. I SUPPOSE, YES, I CAN THINK OF SOME.

22 Q. LIKE, FOR EXAMPLE, IF YOU'RE LIVING ON A FARM AND  
23 YOU HEAR A ROOSTER CROWING AND IT'S NOT LIGHT YET AND THEN  
24 THE SUN RISES, YOU COULD MAKE THE MISTAKE OF CONCLUDING,  
25 BECAUSE THERE'S A TEMPORAL RELATIONSHIP WITH THE ROOSTER  
26 ALWAYS CROWING AND THEN LATER ON THE SUN COMES UP, THAT  
27 SOMEHOW THE ROOSTER IS CAUSING THE SUN TO COME UP; RIGHT?

28 A. I WOULDN'T, BUT I CAN IMAGINE THE SITUATION.

JUDITH ANN OSSA, CSR NO. 2310

0031

1 WE TALKED ABOUT WHAT WE CALL TEMPORAL SEQUENCE,  
2 WHAT THAT MEANS, HOW TO USE IT IN CAUSAL INFERENCE, WHEN YOU  
3 SAY -- I THINK IN YOUR QUESTION YOU SAID TO ME -- WELL, NO.  
4 WE WOULD CONSIDER CAUSE AND EFFECT MUCH MORE CAREFULLY.

5 THERE ARE STUDIES THAT LIGHT COMES UP AND AFFECTS  
6 THE PINEAL GLANDS, LITTLE GLANDS THAT WE ALL HAVE. AND THAT  
7 DOES LEAD TO THE EXCRETION OF A CHEMICAL CALLED MELATONIN  
8 THAT IS THOUGHT TO RELATE TO SOME BIRD BEHAVIOR SUCH AS  
9 THAT.

10 BUT NEVERTHELESS, I WOULD ALWAYS BRING IT RIGHT  
11 TO THE BIOLOGICAL RELATIONSHIP STUDY, ALL THE ASPECTS OF  
12 CAUSE AND EFFECT, AND BRING IN OTHER INFORMATION, NOT THAT  
13 JUST ONE THING HAPPENED FIRST.

14 Q. ANOTHER EXAMPLE YOU ARE PROBABLY AWARE  
15 OF -- BECAUSE YOU HAVE READ SOME DEPOSITIONS IN THE CASE,  
16 HAVEN'T YOU?

17 A. I SCANNED THEM.

18 Q. DO YOU REMEMBER A TIME WHEN, FOR A WHILE, PEOPLE  
19 THOUGHT WHEN WE HAD THAT TERRIBLE EPIDEMIC OF POLIO ABOUT  
20 THE TIME -- I GUESS YOU AND I ARE PROBABLY ROUGHLY THE SAME  
21 AGE -- WHEN WE WERE GROWING UP, THAT TERRIBLE EPIDEMIC OF  
22 POLIO, AND THERE WERE SOME PEOPLE THAT WERE STATING THAT IT  
23 WAS LIKE AS IF THE POLIO WAS BECAUSE OF INCREASED  
24 CONSUMPTION OF THESE NEW SOFT DRINKS, BECAUSE IT APPEARED  
25 THAT AT THE SAME TIME PEOPLE WERE DRINKING MORE SOFT DRINKS,  
26 THEY WERE GETTING MORE POLIO? DO YOU REMEMBER THAT?

27 A. NO.

28 Q. OKAY. DO YOU REMEMBER THAT IT TURNED OUT THAT

JUDITH ANN OSSA, CSR NO. 2310

0032

1 WHAT HAPPENED WAS THAT THE REASON THERE WAS THAT ASSOCIATION  
2 BETWEEN INCREASED CONSUMPTION OF SOFT DRINKS AND INCREASED  
3 INCIDENCE OF POLIO IN YOUNGSTERS WAS THAT KIDS WERE DRINKING  
4 MORE SOFT DRINKS WHEN IT'S SUMMERTIME, IT'S HOTTER, AND THAT  
5 WAS THE TIME WHEN THE POLIO VIRUS SEEMED TO CAUSE ITS HAVOC  
6 TO A GREATER EXTENT BECAUSE OF WHAT THE POLIO BUG DOES?  
7 DOES THAT MAKE SENSE?

8 A. NO.

9 Q. OKAY. YOU ARE NOT AWARE OF THAT HISTORY?

10 A. NO. NO. I COULD TELL YOU EXAMPLES LIKE THAT,  
11 BUT NOT THAT PARTICULAR ONE, NO. I MEAN, PEOPLE --

12 Q. GIVE ME AN EXAMPLE, IF YOU WOULD, THAT YOU CAN  
13 REMEMBER LIKE THAT.

14 A. WELL, IT USED TO BE THOUGHT THAT BECAUSE PEOPLE

15 WHO LIVED NEAR SWAMPS GOT MALARIA, THAT THERE'S SOMETHING  
16 ABOUT THE HUMAN AIR NEAR SWAMPS THAT CAUSES MALARIA.  
17 IT HAPPENS THAT THAT IS A PART OF THE TRUTH IN  
18 THAT MOSQUITOS ARE NEAR THE SWAMPS. IT WAS LATER FOUND OUT  
19 THAT THAT WAS THE VECTOR THAT CAUSED IT.  
20 BUT THE INITIAL ASSOCIATION LIKE THAT MAY HAVE  
21 WITHIN IT SOMETHING THAT RELATES TO CAUSE OR MAY NOT. YOU  
22 HAVE TO BE VERY CAUTIOUS ABOUT IT.  
23 Q. DO YOU AGREE WITH ME, THEREFORE, THAT STATISTICAL  
24 METHODS CANNOT ESTABLISH PROOF OF A CAUSAL RELATIONSHIP IN  
25 SUCH AN ASSOCIATION?  
26 MS. CHABER: I WOULD OBJECT TO THE "THEREFORE"  
27 AS ARGUMENTATIVE.  
28 THE COURT: LET'S ASSUME THE QUESTION DIDN'T  
JUDITH ANN OSSA, CSR NO. 2310

0033

1 HAVE THE "THEREFORE" IN IT.  
2 DID YOU UNDERSTAND THE QUESTION WITHOUT THE WORD  
3 "THEREFORE"?  
4 WHY DON'T YOU REASK IT.  
5 MR. BARRON: I WILL REASK IT. SURE, YOUR HONOR.  
6 Q. DO YOU AGREE THAT STATISTICAL METHODS, DOCTOR,  
7 CANNOT ESTABLISH PROOF OF CAUSAL RELATIONSHIP IN AN  
8 ASSOCIATION?  
9 A. I DO. IT TAKES EPIDEMIOLOGY.  
10 Q. NOW, SPEAKING OF THAT, YOU TALKED ABOUT SOME  
11 EARLIER VIEWS OR OPINIONS OR HYPOTHESES, THEORIES -- I'M NOT  
12 SURE WHAT WORD YOU USED -- ABOUT CAUSES FOR LUNG CANCER FROM  
13 AN EPIDEMIOLOGICAL POINT OF VIEW. YOU CALLED THEM RED  
14 HERRINGS.  
15 DO YOU REMEMBER THAT?  
16 A. NO. YOU MISUNDERSTOOD ME, COUNSEL. IT WASN'T AN  
17 EPIDEMIOLOGICAL VIEW.  
18 THESE WERE WHAT I AT THE TIME CALLED QUAIN'T IDEAS  
19 RAISED BY THE TOBACCO INDUSTRY.  
20 Q. WELL, THAT'S WHY I BROUGHT IT UP.  
21 DO YOU REMEMBER THE CONSTITUTIONAL HYPOTHESIS AS  
22 BEING PUT FORTH? THAT WAS THE ONE ABOUT SOMETHING WITH THE  
23 PEOPLE'S NERVOUS SYSTEM, THAT THAT WAS ACTUALLY PUT FORTH BY  
24 THE MAYO CLINIC?  
25 A. I DON'T KNOW. I DON'T RECALL.  
26 Q. DO YOU HAVE A DOCUMENT FROM A TOBACCO --  
27 ACTUALLY, STRIKE THAT.  
28 DO YOU HAVE A DOCUMENT, FIRST OF ALL, FROM PHILIP  
JUDITH ANN OSSA, CSR NO. 2310

0034

1 MORRIS, WHERE PHILIP MORRIS SAID THAT THEY WERE PUTTING  
2 FORTH THIS HYPOTHESIS AS THEIR PRODUCT OR WORK?  
3 A. NO DOCUMENTS ON THAT NOW.  
4 WHAT I DID RECALL AT THE TIME I READ THOSE  
5 THINGS, THAT MOST OF THEM WERE ORIGINATING FROM SCIENTISTS  
6 WHO WERE SUPPORTED BY TOBACCO COMPANIES.  
7 BUT I CAN'T GO DOWN TO EVERY LAST LINE OF MY  
8 FIRST LECTURE THAT I THINK I GAVE MANY YEARS AGO.  
9 Q. DOCTOR, IN FAIRNESS, YOU'VE TESTIFIED BEFORE IN  
10 COURT A NUMBER OF TIMES; CORRECT?  
11 A. CORRECT.  
12 Q. IN FACT, YOU'VE TESTIFIED, I THINK YOU ESTIMATED  
13 WHEN I TOOK YOUR DEPOSITION RECENTLY, OVER 100 TIMES?  
14 A. CORRECT.  
15 Q. AND BY THE WAY, IN TERMS OF YOUR WORK UNRELATED  
16 TO LEGAL EXPERT WORK -- AS I UNDERSTOOD THIS MORNING, YOU  
17 TOLD US THAT -- ACTUALLY, WHEN YOU WERE ASKED WHAT YOU DO



18 OVER THERE AT BERKELEY, YOU GAVE US TWO THINGS. YOU GAVE  
19 US, NO. 1, TEACHING IS HOW YOU SPENT YOUR TIME, AND NO. 2  
20 RESEARCH.  
21 HOW MUCH OF YOUR TIME DO YOU SPEND TEACHING?  
22 A. IT'S AROUND ABOUT 40 PERCENT TEACHING, 40 PERCENT  
23 IN RESEARCH. AND THEN I DO ADMINISTRATIVE THINGS, AND  
24 COMMITTEES AND THINGS LIKE THAT.  
25 Q. YOU DIDN'T MENTION ANY EXPERT WORK THAT YOU DO IN  
26 THIS LEGAL FIELD.  
27 HOW MUCH OF YOUR TIME IS SPENT DOING THAT?  
28 A. IT'S ABOUT 10 OR 15 PERCENT. BUT A LOT OF IT IS  
JUDITH ANN OSSA, CSR NO. 2310

0035

1 ON WEEKENDS, AT NIGHTS.  
2 WHEN I REFER TO WHAT I MAINLY DO, IT'S IN THE  
3 CONTEXT OF MY UNIVERSITY POSITION, WHICH DOES ALLOW US TO  
4 SPEND THE EQUIVALENT OF A DAY A WEEK DOING CONSULTING WORK.  
5 Q. I'M SORRY. YOU SAID HOW MUCH OF YOUR TIME, 10 TO  
6 15 PERCENT?  
7 A. OF MY TOTAL WORK WEEK, YES.  
8 Q. NOW, THAT COMPARES THOUGH, ACTUALLY, WITH THE  
9 FACT THAT YOUR INCOME IS GREATER FROM THAT THAN YOUR  
10 TEACHING BECAUSE, ACTUALLY, ONE-THIRD OF YOUR INCOME COMES  
11 FROM THIS LEGAL WORK, DOESN'T IT?  
12 A. WELL, I DON'T HAVE A SEPARATE INCOME FOR  
13 TEACHING. MY INCOME AT THE UNIVERSITY IS FOR MY TOTAL  
14 APPOINTMENT.  
15 IT IS TRUE, THOUGH, THAT AROUND ABOUT A THIRD OF  
16 MY INCOME DOES COME FROM MEDICAL/LEGAL CONSULTING.  
17 Q. OKAY. BY THE WAY, I DO HAVE YOUR DEPOSITION  
18 HERE. I THOUGHT MAYBE YOU WERE SAYING SOMETHING MAYBE  
19 SLIGHTLY DIFFERENT.  
20 BUT AS I REACH FOR IT, I HEARD WHAT WE HEARD AT  
21 THE DEPOSITION, SO LET ME JUST HAND IT TO YOU. I MIGHT HAVE  
22 TO REFER TO THAT LATER ON TO SAVE TIME.  
23 MS. CHABER: COULD WE STRIKE THE COMMENTS OF  
24 COUNSEL, YOUR HONOR, ON THE SPEECHES?  
25 THE COURT: THE COMMENTS OF COUNSEL ARE NOT  
26 EVIDENCE ANYWAY.  
27 MR. BARRON: NO. I'M SORRY.  
28 Q. WELL, SOME OF THE WORK YOU'VE DONE AS A WITNESS  
JUDITH ANN OSSA, CSR NO. 2310

0036

1 HAS BEEN FOR MS. CHABER AND HER LAW FIRM; CORRECT?  
2 A. CORRECT.  
3 Q. ON NUMEROUS OCCASIONS?  
4 A. NOT VERY MANY. A NUMBER OF OCCASIONS.  
5 Q. HOW FREQUENTLY EACH YEAR?  
6 A. THESE WORDS "OCCASIONAL" AND "NUMBERS" HAVE  
7 DIFFERENT MEANINGS. I THINK -- IN TERMS OF THE WARTNICK  
8 FIRM, AS IT IS NOW KNOWN, I DON'T KNOW. ONCE, TWICE, THREE  
9 TIMES A YEAR, SOMETHING LIKE THAT, BUT I'M NOT SURE.  
10 I DON'T THINK, IN MY MIND'S EYE, IN TERMS OF  
11 SEPARATING THEM LIKE THAT.  
12 Q. AND HAVE YOU BEEN PART OF THE GROUP OF PEOPLE WHO  
13 HAVE TESTIFIED IN HER CASES THAT INCLUDE, FOR EXAMPLE, DR.  
14 HORN AND DR. HAMMAR?  
15 A. I DON'T UNDERSTAND THE QUESTION. I'M AWARE THAT  
16 THEY HAVE TESTIFIED IN OTHER CASES I'VE BEEN INVOLVED WITH,  
17 IF THAT ANSWERS YOUR QUESTION.  
18 Q. OKAY. NOW, IN LIGHT OF THAT, AM I CORRECT THAT  
19 YOU HAVE SOME UNDERSTANDING OF WHAT THIS CASE GENERALLY IS  
20 ABOUT THAT MS. CHABER IS HERE TO OFFER YOU AS AN EXPERT IN?

21 A. I'M SORRY. I DON'T UNDERSTAND THE PART AT THE  
22 BEGINNING, "IN THE LIGHT OF."  
23 IN THE LIGHT OF WHAT?  
24 Q. IN THE LIGHT OF YOUR EXPERIENCE OF TESTIFYING 100  
25 TIMES, IN LIGHT OF THE FACT THAT YOU'VE TESTIFIED, WORKED  
26 WITH HER FIRM TWO TO THREE TIMES A YEAR, IN LIGHT OF THE  
27 FACT YOU HAVE BEEN INVOLVED IN CASES THAT HAVE INVOLVED  
28 DR. HORN AND DR. HAMMAR, ARE YOU COMFORTABLE THAT YOU HAVE  
JUDITH ANN OSSA, CSR NO. 2310

0037

1 AT LEAST A GENERAL UNDERSTANDING WHAT THIS CASE IS ABOUT?  
2 A. WELL, I HAVE PREVIOUSLY BEEN AN EXPERT, SO I HAVE  
3 AN UNDERSTANDING.  
4 I DON'T KNOW WHAT YOUR REFERENCE TO DR. HORN AND  
5 DR. HAMMAR MEANS. THAT'S NOT RELEVANT TO MY OPINIONS.  
6 Q. WELL, I WANT TO GET BACK TO YOUR COMMENT ABOUT  
7 WHO IT WAS, WHETHER THE MAYO CLINIC OR SOMEBODY ELSE, WHO  
8 CAME UP WITH THIS IDEA ABOUT PEOPLE'S CONSTITUTION OR THEIR  
9 NERVOUS SYSTEM.  
10 IN LIGHT OF THE FACT THAT YOU WERE GOING TO OFFER  
11 TESTIMONY ABOUT THAT, DID YOU THINK IT WAS AT ALL IMPORTANT  
12 TO TRY TO BRING SOME DOCUMENTS WITH YOU THAT WOULD SHOW THAT  
13 THIS DEFENDANT, PHILIP MORRIS, ACTUALLY SAID THAT AS THE  
14 PROPONENT FOR THE THEORY?  
15 A. NO. I WASN'T REPRESENTING THAT PHILIP MORRIS DID  
16 IT. I JUST NOTED THAT AS BEING QUAIN'T THEORIES. AND I WAS  
17 AWARE OF THEM FROM THAT TIME, SOME OF THEM.  
18 AND THE BULK OF THEM, AS I RECALL, WERE PROMOTED  
19 AND PUT FORTH BY SCIENTISTS WHO EITHER WORKED FOR OR WERE  
20 LINKED TO THE TOBACCO INSTITUTE AND TOBACCO COMPANIES. BUT  
21 I CAN'T VOUCH FOR IT INDIVIDUALLY.  
22 I JUST WANT TO MAKE SURE THAT THE JURY  
23 UNDERSTANDS. AND I'M RECALLING FROM WHAT HAPPENED IN, I  
24 THINK, 1972.  
25 Q. YOU HAVE NOW BEEN AS PRECISE AS YOU CAN BE ON  
26 THAT SUBJECT IN TERMS OF THAT FIRST RED HERRING?  
27 A. I COULD GIVE MORE INFORMATION ABOUT WHAT MY  
28 LECTURE WAS ABOUT.

JUDITH ANN OSSA, CSR NO. 2310

0038

1 Q. NO. AS TO WHO IS THE ONE THAT HAD THE RED  
2 HERRING THEORY THAT THEY PROPOSED, HAVE YOU BEEN AS PRECISE  
3 NOW IN GIVING YOUR ANSWER ABOUT THAT?  
4 A. I THINK SO. I DON'T KNOW WHERE SPECIFICALLY THAT  
5 ONE CAME FROM.  
6 Q. NOW, YOU ALSO MENTIONED A SECOND ONE ABOUT A RED  
7 HERRING.  
8 DO YOU KNOW WHO SIR RICHARD DOLL IS?  
9 A. YES, I DO.  
10 Q. AS A MATTER OF FACT, WAS THAT A HYPOTHESIS THAT  
11 HE PUBLISHED?  
12 A. NO, THAT WAS A REASON THAT TOBACCO DOESN'T CAUSE  
13 LUNG CANCER.  
14 IN FACT, WHAT HE POINTED OUT, AS I RECALL, HE MAY  
15 HAVE BEEN THE PERSON WHO NOTED THAT THERE WAS A GOOD  
16 EXPLANATION FOR THAT, THAT IT MAY RELATE TO THE EXPENSE OF  
17 THE SMOKING OF A CIGARETTE.  
18 Q. DOCTOR, AGAIN, CAN YOU IDENTIFY FOR ME PRECISELY  
19 WHO IT WAS THAT CAME UP WITH WHAT YOU CALLED A RED HERRING?  
20 A. NO, I CAN'T, COUNSEL. BUT THE RED HERRING AGAIN  
21 WAS IT'S NOT TOBACCO CAUSING THE LUNG CANCER BECAUSE OF THAT  
22 PIECE OF EVIDENCE.  
23 BUT I CAN'T SPECIFICALLY SAY WHAT NEWSPAPER

24 CUTTING, WHAT SCIENTIFIC ARTICLE CUTTING OR WHO PUT IT  
25 FORTH, NO.

26 Q. DO YOU HAVE WITH YOU A DOCUMENT THAT WOULD  
27 DEMONSTRATE THAT THIS DEFENDANT, OR EVEN THE TOBACCO  
28 INSTITUTE, ITS TRADE ASSOCIATION THAT IT PARTICIPATED IN,  
JUDITH ANN OSSA, CSR NO. 2310

0039

1 WAS THE ONE THAT CREATED THAT RED HERRING?

2 A. I DO NOT.

3 Q. THE ARSENIC RED HERRING WAS THE THIRD ONE YOU  
4 MENTIONED.

5 WAS THAT PUBLISHED ACTUALLY IN THE 1964 SURGEON  
6 GENERAL'S REPORT?

7 A. THERE WAS MENTION OF ARSENIC CONTAMINANTS IN  
8 SURGEON GENERAL'S REPORTS. I DON'T REMEMBER WHICH ONE.

9 BUT NO STATEMENT IN ANY OF THE SURGEON GENERAL'S  
10 REPORTS THAT I RECALL SUGGESTED THAT ARSENIC WAS THE CAUSE  
11 OF LUNG CANCER TO SMOKERS AND NOT OTHER CONSTITUENTS OF THE  
12 SMOKE.

13 Q. WHO CREATED THAT RED HERRING AND WHEN, DOCTOR?

14 A. I DON'T KNOW.

15 Q. AGAIN, HAVE YOU MADE ANY EFFORT TO TRY TO  
16 DETERMINE WHETHER PHILIP MORRIS, THIS DEFENDANT, CREATED  
17 THAT RED HERRING?

18 A. NO, OF COURSE NOT. THAT'S NOT WHAT I'M HERE TO  
19 TESTIFY ABOUT.

20 Q. HAVE YOU TRIED TO DETERMINE WHETHER THE TOBACCO  
21 INSTITUTE OR ANY TRADE ASSOCIATION WITH WHICH THIS DEFENDANT  
22 WAS ASSOCIATED WAS THE ONE THAT CREATED WHAT YOU CALLED A  
23 RED HERRING?

24 A. NO.

25 Q. OKAY. BY THE WAY, CAN YOU GIVE US AN IDEA FOR  
26 HOW LONG A PERIOD YOUR TIME OR EFFORT HAS BEEN 10 TO 15  
27 PERCENT AND YOUR INCOME HAS BEEN A THIRD FROM THIS KIND OF  
28 WORK THAT YOU'RE DOING, INCLUDING TESTIFYING IN COURT?

JUDITH ANN OSSA, CSR NO. 2310

0040

1 A. WELL, ROUGHLY 10 YEARS. WHEN I FIRST CAME TO  
2 CALIFORNIA IN '83, I THINK ABOUT '84, I STARTED TESTIFYING.  
3 IT INCREASED TO ROUGHLY THAT AMOUNT AFTER THREE,  
4 FOUR YEARS.

5 Q. HAVE YOU WRITTEN ON THE SUBJECT AT ALL, BEING AN  
6 EXPERT WITNESS?

7 A. NO.

8 Q. HAVE YOU TALKED ABOUT IT IN ANY TALKS OR  
9 SPEECHES?

10 A. YES.

11 Q. AND HAVE YOU DESCRIBED THE COURT SYSTEM AND WHAT  
12 IT'S LIKE TO BE A WITNESS?

13 A. YES. IN TEACHING EPIDEMIOLOGISTS, I TELL THEM  
14 THAT THEY MAY IN THEIR CAREER BE ASKED TO BE AN EXPERT. AND  
15 I DO AT TIMES REFER TO, VERY BRIEFLY, SOME OF THE ISSUES  
16 THAT ARE INVOLVED.

17 Q. NOW, ONE OF THE THINGS THAT A WITNESS CAN DO IS  
18 JUST GIVE TESTIMONY LIKE YOU ARE NOW, TALKING AND HAVING  
19 PEOPLE LISTEN TO IT; CORRECT? THAT'S ONE THING THAT A  
20 WITNESS CAN DO?

21 A. I THOUGHT THAT'S WHAT WE DID IN COURT.

22 Q. ALSO ON THE BOARD OR ON THE BUTCHER PAPER, YOU  
23 WROTE FOUR THINGS DOWN.

24 AND WAS IT YOUR HOPE OR INTENT TO HAVE THE JURORS  
25 WRITE DOWN THAT LITTLE FORMULA OF 1, 2, 3, 4? IS THAT WHY  
26 YOU WROTE IT?

27 A. NO. I WROTE IT TO BE -- TO SAY SOMETHING THAT I  
28 THOUGHT THE EVIDENCE WAS VERY CLEAR ON. I WISHED TO PRESENT  
JUDITH ANN OSSA, CSR NO. 2310

0041

1 THAT.

2 AND IN ALL MY TEACHING, I FIND IT HELPS ME TO  
3 SLOW DOWN, SAY THINGS CLEARLY, AND WRITE THEM UP. AND  
4 OBVIOUSLY, IT GIVES AN OPPORTUNITY FOR PEOPLE TO TAKE NOTES,  
5 IF THEY WISH TO.

6 Q. BUT YOU SAID A LOT OF THINGS AND YOU'VE WRITTEN A  
7 FEW THINGS IN COMPARISON WITH WHAT YOU HAVE SAID.

8 DO YOU AGREE WITH ME ON THAT?

9 A. CERTAINLY.

10 Q. YOU WERE SELECTIVE IN WHAT YOU DECIDED TO WRITE  
11 ON THE BUTCHER PAPER; CORRECT?

12 A. YES, ABOUT AS FAR AS I WAS ALLOWED TO BE. I  
13 THINK --

14 Q. AND YOU REALIZED, I GUESS, THAT CAUSE WAS THE  
15 ISSUE UPON WHICH YOU WERE BEING CALLED TO TESTIFY ABOUT;  
16 RIGHT?

17 A. CORRECT.

18 Q. AND SO THIS WAS SORT OF A FORMULA THAT YOU WERE  
19 OFFERING FOR AN EVALUATION OF CAUSE; RIGHT?

20 A. NO. I WOULDN'T CALL IT -- YOU CALLED IT A  
21 FORMULA.

22 I'D SAY THE ESSENCE OF THE ARGUMENT TO ME ABOUT  
23 CAUSE IS VERY SIMPLE, AND I JUST PUT IT UP. I CERTAINLY  
24 WOULDN'T CALL IT A FORMULA.

25 Q. SO IT'S AN ARGUMENT. IN FACT, YOU CALLED IT  
26 SOMETHING THAT WASN'T TECHNICALLY DIFFICULT; CORRECT?

27 A. I THINK I SAID THAT.

28 Q. IN FACT, YOU SAID IT WAS UTTERLY CLEAR?

JUDITH ANN OSSA, CSR NO. 2310

0042

1 A. PROBABLY. YES, IT IS UTTERLY CLEAR.

2 Q. NOW, BEFORE DECIDING ALL THIS, YOU HAD TO LOOK  
3 AT, FIRST OF ALL, DID YOU NOT, WHAT THE CLINICAL EVIDENCE  
4 WAS IN THIS CASE?

5 A. WELL, I DID LOOK TO SEE IF IT WAS ABOUT LUNG  
6 CANCER. I WAS AWARE THAT I WOULDN'T BE TESTIFYING AS TO  
7 WHETHER OR NOT IT WAS LUNG CANCER. I WOULDN'T BE PROVIDING  
8 PRIMARY EVIDENCE ON THAT AS A WITNESS.

9 BUT I HAVE THE UNDERSTANDING OF WHAT IT WAS ABOUT  
10 AND THERE WAS A DIAGNOSIS OF LUNG CANCER.

11 Q. NOW, YOU ARE NOT A CLINICIAN?

12 A. THAT IS CORRECT.

13 Q. BUT IN ORDER TO COME UP WITH THIS IDEA WHICH YOU  
14 WROTE ON THE BOARD FOR US AND YOUR BENEFIT, DID YOU TRY TO  
15 MARSHALL ALL THE EVIDENCE ON THAT FIRST QUESTION?

16 A. WHAT DO YOU MEAN "MARSHALL," COUNSEL? I DON'T  
17 UNDERSTAND.

18 IT'S BASED ON MY EXPERIENCE OVER MANY, MANY  
19 YEARS, BOTH AS A TEACHER, A RESEARCHER AND A STUDENT OF  
20 CANCER, ITS CAUSES, AND LUNG CANCER.

21 Q. YOU DON'T KNOW WHAT I MEAN BY THE WORD  
22 "MARSHALL"?

23 A. I DON'T KNOW WHAT YOU MEAN BY THE QUESTION,  
24 COUNSEL. IF YOU SAY "MARSHALL," I MEAN, I COULD SPEND THE  
25 NEXT YEAR PULLING TOGETHER OR TRYING TO ALL THE ARTICLES  
26 I'VE EVER READ THAT MIGHT RELATE TO LUNG CANCER AND SMOKING  
27 AND THE DIAGNOSIS OF LUNG CANCER. OBVIOUSLY, THAT'S VASTLY  
28 CLEAR.

JUDITH ANN OSSA, CSR NO. 2310

0043

1 IT SEEMED TO ME SUCH A STRAIGHTFORWARD CASE,  
2 SIMPLY NOT SOMETHING THAT WAS NEEDED.

3 Q. DOCTOR, I'M ONLY NOW ASKING YOU ABOUT QUESTION  
4 NO. 1.

5 DO YOU WANT TO TURN AROUND AND LOOK AT THAT?

6 A. I'VE SEEN IT.

7 Q. OKAY. MY QUESTION IS, FIRST OF ALL, YOU  
8 UNDERSTOOD THAT THIS WAS --

9 A. CAN I -- I'M SORRY TO INTERRUPT. BUT IN TURNING  
10 AROUND, I WAS ANSWERING ABOUT THE WHOLE CONCEPT.

11 AS FAR AS THE FIRST LUNG CANCER PART GOES, I AM  
12 DRAWING, IT IS TRUE, ON MY EXPERIENCE IN EPIDEMIOLOGICAL  
13 STUDIES WHERE WE INCLUDE LUNG CANCER.

14 BUT NEVERTHELESS, I'M HERE WITH THE UNDERSTANDING  
15 THAT OTHERS WILL BE TESTIFYING PRIMARILY AS TO THE CLINICAL  
16 DIAGNOSIS AND NOT MYSELF.

17 I DIDN'T SEE MY EXERCISE TO MARSHALL EVIDENCE  
18 THAT THE PATIENT HAS LUNG CANCER.

19 Q. NOW, YOU SORT OF LOST ME.

20 AS AN EXPERT, THE LAW ENTITLES YOU TO OFFER AN  
21 OPINION.

22 YOU UNDERSTAND THAT THAT'S THE WAY IT WORKS?  
23 THAT IS WHAT YOU'VE DONE 100 TIMES BEFORE; CORRECT?

24 A. I DIDN'T HEAR THE FIRST PART OF THAT.

25 I OFFER OPINIONS. YES, I DO.

26 Q. OKAY.

27 A. BASED ON UNDERSTANDINGS.

28 Q. AND YOU'VE OFFERED FOUR OPINIONS THAT YOU WROTE  
JUDITH ANN OSSA, CSR NO. 2310

0044

1 ON THE BOARD.

2 AND THE FIRST ONE IS THAT "THE PATIENT HAS LUNG  
3 CANCER (MOST PROBABLY)," CORRECT?

4 A. NO. THAT IS -- THESE AREN'T A LIST OF OPINIONS,  
5 COUNSEL. THIS IS A LIST OF THE INFORMATION ON WHICH I BASED  
6 MY OPINION.

7 THE FIRST ONE IS MY UNDERSTANDING, BASED ON WHAT  
8 I HAD READ, THE CLINICAL REPORTS, BASED ON MY EXPERIENCE,  
9 THAT THE PATIENT HAS LUNG CANCER, OR PROBABLY DID, BUT BEING  
10 AWARE THAT OTHERS WOULD TESTIFY AS TO THE EVIDENCE FOR AND  
11 AGAINST THAT, CLINICALLY.

12 Q. WHEN YOU BASE AN OPINION ON AN UNDERSTANDING  
13 THAT, IN TURN, YOU TURN TO OTHER PIECES OF INFORMATION TO  
14 DEVELOP, YOU AGREE WITH ME THAT YOUR ULTIMATE OPINION IS  
15 ONLY AS GOOD AS YOUR UNDERSTANDING; CORRECT?

16 A. WELL, I WOULDN'T SAY "ONLY AS GOOD." BUT YOU ARE  
17 CORRECT, THAT IF I HAVE INDICATED PROBABLY -- IF IT'S  
18 IMPROBABLE THE PATIENT HAS LUNG CANCER, THEN OBVIOUSLY MY  
19 CONCLUSIONS DON'T FOLLOW.

20 Q. AND IN ORDER TO DETERMINE HOW GOOD YOUR  
21 UNDERSTANDING IS, YOU HAVE TO LOOK AT THE EVIDENCE, THE  
22 FACTS, THE INFORMATION AND TRY TO GATHER IT AND LOOK AT IT,  
23 DON'T YOU?

24 A. WELL, I DO LOOK AT IT, BUT I'M NOT TRYING TO BE  
25 THE DEFINITIVE PERSON MAKING THAT CONCLUSION, COUNSEL.

26 I DON'T DO PATHOLOGY. I LOOK AT THE PATHOLOGY  
27 REPORT, BUT NEVERTHELESS, THE PATHOLOGIST NEEDS TO TALK  
28 ABOUT THE PATHOLOGY REPORT.

JUDITH ANN OSSA, CSR NO. 2310

0045

1 SO I DON'T QUITE UNDERSTAND YOUR QUESTION THERE.

2 Q. WELL, AS A MATTER OF FACT, WHEN YOU WROTE NO. 1,

3 DID YOU HAVE IN MIND WHAT YOU HAD IN MIND IN YOUR  
4 DEPOSITION, THAT IN FACT THE PATHOLOGIST IN THIS CASE YOU  
5 THOUGHT WAS LOOKING AT TISSUE THAT HAD BEEN TAKEN FROM  
6 WITHIN THE LUNG?

7 A. COULD YOU REPEAT THE QUESTION, COUNSEL.

8 MR. BARRON: SURE. COULD SHE JUST READ IT BACK.

9 THE COURT: SURE.

10 (RECORD READ)

11 MR. BARRON: THANK YOU.

12 THE WITNESS: MY RECOLLECTION IS THAT THERE HAD  
13 BEEN AN IMMEDIATE --WHAT'S THE WORD -- A BIOPSY TAKEN, THAT  
14 IT WAS FROM THE HILAR MASS.

15 NOW, THAT I UNDERSTOOD, IN THE WAY I WOULD THINK  
16 OF IT, AND THAT THE HILUM ITSELF IS PART OF THE LUNG. WE  
17 DISCUSSED THAT AT LENGTH IN THE DEPOSITION.

18 I DO KNOW THAT THE INTERPRETATION WAS THAT THE  
19 ORIGIN OF THIS WAS THE LUNG.

20 BUT SPECIFICALLY, AS FAR AS THE ANATOMICAL  
21 LOCATION OF THE PRECISE BIOPSY, I DO REMEMBER THAT WE SPENT  
22 A LOT OF TIME IN THE DEPOSITION DISCUSSING THAT, AND I DON'T  
23 RECALL EXACTLY THE CONTENT OF THAT.

24 Q. TURN IN YOUR DEPOSITION, IF YOU WOULD, TO PAGE  
25 31. AND I WON'T TAKE THE TIME TO READ IT ALL.

26 AND IF YOU CAN ANSWER THIS QUESTION YES OR NO,  
27 DOCTOR, I'D APPRECIATE IT. IF YOU NEED TO ADD TO IT  
28 AFTERWARDS, YOU MAY.

JUDITH ANN OSSA, CSR NO. 2310

0046

1 IS THAT NOT YOUR DEPOSITION?

2 A. THAT IS VOLUME II.

3 YOU SAID PAGE 31?

4 THE COURT: YES. I DON'T HAVE VOLUME I.

5 MR. BARRON: I DON'T HAVE ONE BEFORE YOU. I'M  
6 SORRY, YOUR HONOR.

7 Q. HAVE YOU FOUND PAGE 31?

8 A. I HAVE.

9 Q. IF YOU LOOK QUICKLY, BECAUSE YOU CAN READ FASTER  
10 THAN WE CAN ACTUALLY SPEAK OUT LOUD, IF YOU LOOK AT LINE 11,  
11 YOUR ANSWER STARTS ALL THE WAY --

12 MS. CHABER: I WOULD --

13 MR. BARRON: MAY I JUST GET MY QUESTION OUT?

14 MS. CHABER: YES.

15 MR. BARRON: Q. -- DOWN TO PAGE 32, LINE 4. DO  
16 YOU AGREE THAT YOU INDICATED THERE THREE TIMES THAT THE MASS  
17 WAS IN THE LUNG?

18 A. (EXAMINING)

19 I'M CONFUSED, COUNSEL. I'M SORRY. YOU WERE  
20 REFERRING TO THE BIOPSY BEFORE. I DID SAY THERE WAS X-RAY  
21 EVIDENCE OF A MASS IN THE LUNG.

22 Q. OKAY.

23 A. RIGHT DOWN TO WHERE?

24 AND THERE IS EVIDENCE OF SOMETHING IN THE LUNG  
25 THAT LED TO IT BEING BIOPSIED.

26 Q. I'M TAKING YOU THROUGH THIS TO SAVE TIME.

27 THEN TURN TO PAGE 43, LINE 11 TO LINE 17. IF  
28 YOU'D LOOK AT THAT.

JUDITH ANN OSSA, CSR NO. 2310

0047

1 A. (EXAMINING)

2 I SEE IT.

3 Q. OKAY. WAS IT YOUR IMPRESSION AT THE TIME THAT  
4 WHETHER THE TISSUE WAS TAKEN FROM THE HILAR AREA OR WITHIN  
5 THE LUNG, IT IN ESSENCE WAS LUNG TISSUE THAT WAS TAKEN AND

6 BIOPSIED?  
7 A. THE IMPRESSION WHEN I READ THE MATERIAL IS THAT  
8 THE PATHOLOGIST LOOKED AT THE BIOPSY AND DIAGNOSED THE LUNG  
9 CANCER. THAT'S WHAT MY IMPRESSION WAS IN LOOKING AND  
10 READING THE RECORDS THAT WERE SENT TO ME.  
11 Q. WOULD YOU PULL THAT RECORD OUT FROM THE  
12 PATHOLOGIST, AND PLEASE INDICATE TO ME WHERE HE SAYS THAT  
13 HIS IMPRESSION IS THAT THIS IS LUNG CANCER.  
14 COULD YOU TELL ME WHICH RECORD OF THE  
15 PATHOLOGIST? THERE'S ONLY ONE PATHOLOGY REPORT?  
16 A. THAT'S NOT TRUE, COUNSEL. THERE'S ALSO A  
17 STATEMENT AND THERE'S A DEPOSITION.  
18 Q. THERE IS NO DEPOSITION OF THE PATHOLOGIST IN THIS  
19 CASE.  
20 A. I HAVE SOME OF THE MATERIAL. I NOTED THE REPORT  
21 BY DR. HAMMAR --  
22 Q. WELL, LET ME STOP YOU RIGHT THERE AND INTERRUPT,  
23 IF I MIGHT.  
24 YOU SEE DR. HAMMAR WASN'T INVOLVED IN THE  
25 CLINICAL TREATMENT OF THIS PATIENT, WAS HE?  
26 A. I DON'T KNOW.  
27 Q. OKAY. DR. HAMMAR, YOU KNOW FROM OTHER CASES WITH  
28 MS. CHABER, HOWEVER; CORRECT?

JUDITH ANN OSSA, CSR NO. 2310

0048

1 A. I KNOW WHO HE IS, YES. I HAVE MET HIM.  
2 Q. I WANT YOU TO ASSUME THAT HE WASN'T THE ONE WHO  
3 WROTE THE PATHOLOGY REPORT AT USC, DOWN IN LOS ANGELES.  
4 WOULD YOU FIND THAT PATHOLOGY REPORT AND INDICATE  
5 WHERE IT'S REPORTED ON THE REPORT, IF IT IS AT ALL, THAT THE  
6 PATHOLOGIST WHO IS REPORTING IT IS REPORTING THAT HE'S FOUND  
7 LUNG CANCER.  
8 A. I DON'T KNOW. I HAVEN'T -- WHAT I WAS REFERRING  
9 TO WAS THE PATHOLOGIST, DR. HAMMAR'S, REPORT, WHO INDICATED  
10 IT WAS A SMALL CELL LUNG CARCINOMA.  
11 Q. OKAY. NOW THAT GETS TO -- IF I COULD, TO THE  
12 OTHER QUESTION, WHICH IS: WHEN YOU ARE GOING ABOUT TRYING  
13 TO DECIDE WHETHER YOU SHOULD WRITE SOMETHING LIKE NO. 1 ON  
14 THE BOARD IN A CASE LIKE THIS -- AND YOU CAN TURN AROUND AND  
15 LOOK AT IT, IF YOU LIKE -- DO YOU TRY TO, AS AN EXPERT,  
16 FAIRLY GO ABOUT TRYING TO LOOK AT WHAT THE REASONABLE  
17 AVAILABLE INFORMATION IS ON THIS SUBJECT BEFORE YOU WRITE  
18 NO. 1?

19 A. NO. WHEN I WROTE NO. 1, I WAS AWARE THAT OTHERS  
20 WOULD BE TESTIFYING IN THIS COURT. AND I'VE EXPLAINED THAT,  
21 COUNSEL.

22 SO WHAT I DO IS, I LOOK AT WHAT I'M SENT. IF  
23 THERE'S EVIDENCE OF LUNG CANCER AND I KNOW IF IT FITS WITH  
24 THE SEQUENCE THAT I'VE SEEN IN STUDIES THAT I'M INVOLVED  
25 WITH, I THEN SAY, "WELL, I SUSPECT THAT THERE WILL BE  
26 EVIDENCE COMING UP IN COURT TO DEMONSTRATE THAT IT IS.

27 SO IF IT'S DETERMINED BY THE JURY THAT THIS  
28 PATIENT HAS LUNG CANCER MOST PROBABLY, THEN THE REST

JUDITH ANN OSSA, CSR NO. 2310

0049

1 FOLLOWS.  
2 BUT I'M NOT HERE TO TESTIFY AS TO ALL THE  
3 EVIDENCE ABOUT NO. 1.  
4 Q. SO YOU'RE, IN EFFECT, SORT OF GIVING THEM AN  
5 APPROACH, LIKE AN INSTRUCTION HOW TO APPROACH THE ISSUE OF  
6 CAUSATION, WITHOUT FILLING IN THE BLANKS?  
7 A. COUNSEL, I THINK THAT IS NOT WHAT I'M DOING. I  
8 CERTAINLY AM NOT INSTRUCTING THE JURY.

9 AS AN EPIDEMIOLOGIST WHO HAS STUDIED LUNG CANCER  
10 FOR MANY YEARS, I'M TELLING THEM THE BEST OF WHAT OF MY  
11 OPINIONS ARE AND HOW I WOULD LOOK AT IT. AND I'M TRYING TO  
12 MAKE IT SOMETHING THAT CAN BE UNDERSTOOD EASILY, BECAUSE IT  
13 IS VERY SIMPLE.

14 Q. BUT GETTING BACK TO THIS, IN ORDER EVEN TO WRITE  
15 THE NO. 1 UP THERE, WHEN YOU WROTE THESE, AND MOST PROBABLY  
16 BEFORE YOU DO THAT, DON'T YOU ORDINARILY WANT TO -- AS AN  
17 EXPERT, IF YOU'RE BEING THOROUGH AND FAIR -- TO TRY TO LOOK  
18 AT THE AVAILABLE EVIDENCE THAT THERE IS?

19 A. NO, COUNSEL. IF I SAW SOME EVIDENCE TO THE  
20 CONTRARY, I'D NOTE IT. BUT OBVIOUSLY, IF THERE'S EVIDENCE  
21 TO THE CONTRARY, THAT WILL COME OUT IN COURT.

22 I CAN'T DO EVERYTHING. I HAVE LIMITED TIME AND I  
23 FOCUS ON MY AREAS OF EXPERTISE. IT'S NOT MY JOB, AS I  
24 REGARD IT, TO DECIDE WHETHER OR NOT THAT IS TECHNICALLY  
25 VALID FROM A CLINICAL OR PATHOLOGICAL STEP.

26 ALL I'M SAYING IS THAT, IF INDEED THE PATIENT HAS  
27 LUNG CANCER MOST PROBABLY, AND IF THE PATIENT SMOKED FOR  
28 MANY YEARS, THEN THE OTHER TWO FOLLOW VERY SIMPLY.

JUDITH ANN OSSA, CSR NO. 2310

0050

1 Q. YOU NEGLECTED TO WRITE THE WORD "IF" UP THERE IN  
2 NO. 1, THOUGH. YOU'RE NOW SPEAKING THE WORD "IF."

3 A. WELL, I'M TALKING THERE IN GENERAL. IF YOU ARE  
4 TALKING ABOUT PATIENTS, IF YOU DECIDE THE FIRST THING IS THE  
5 PATIENT HAS LUNG CANCER, NOW THERE IS NOT ENOUGH ROOM TO PUT  
6 EVERYTHING UP THERE.

7 THE SIMPLE POINT IS THE PATIENT HAS LUNG CANCER.  
8 THE PATIENT SMOKED FOR MANY YEARS. IF IT WERE A LUNG  
9 CANCER, THEN THE IF'S ARE DOWN THERE VERY CLEARLY.

10 Q. I WAS JUST GOING TO SAY YOU HAD ROOM ON 3 OR 4 TO  
11 PUT "IF," BUT YOU DIDN'T HAVE ROOM TO PUT A NUMBER UP  
12 THERE -- YOU HAD ROOM TO PUT THE WORD "IF" FOR 3 AND 4.

13 BUT ARE YOU SUGGESTING THAT THERE WASN'T ROOM UP  
14 THERE IN NO. 1 TO PUT "IF," IF THAT'S REALLY WHAT YOU WERE  
15 SAYING AT THE TIME?

16 A. IF I COULD PLAY WITH PUTTING MORE WORDS UP THERE,  
17 COUNSEL. I'M SAYING THAT IN PUTTING WORDS UP, YOU CAN LOOK  
18 AT THEM, WORK AROUND WITH THEM. THEY ARE NOT PERFECT.

19 BUT I WASN'T TRYING TO --I JUST PUT IT UP FROM  
20 MEMORY. I WAS NOT LOOKING AT NOTES. I THINK IT'S  
21 UNDERSTANDABLE.

22 IF YOU ARE CONCERNED THAT THEY ARE THERE, THEN  
23 THAT'S YOUR -- SO BE IT.

24 Q. DOCTOR, AT THE TIME OF YOUR DEPOSITION, ACTUALLY,  
25 DO YOU REMEMBER THAT YOU WERE AT TIMES ANNOYED WITH ME  
26 BECAUSE YOU SAID IT WAS QUITE SIMPLE THAT THE EVIDENCE  
27 SHOWED THAT MS. HENLEY HAD LUNG CANCER?

28 A. NO. I THINK THAT WHAT WAS QUITE SIMPLE WAS THE  
JUDITH ANN OSSA, CSR NO. 2310

0051

1 EVIDENCE, AND THE WAY I LOOKED AT IT, AND WHAT I HAD DONE  
2 WAS VERY SIMPLE.

3 AND INDEED, I WAS ANNOYED AT YOU BECAUSE THIS  
4 INFORMATION WENT ON AND ON AND ON, AS IF I WAS A  
5 PATHOLOGIST, AS IF I WAS THE CLINICIAN, AND AS IF I WAS  
6 DOING ALL THE DIAGNOSIS.

7 Q. NOW, YOU MENTIONED YOU DIDN'T HAVE TIME, BUT YOU  
8 WERE GIVEN SOME MATERIAL BY MS. CHABER TO REVIEW; CORRECT?

9 A. I WAS GIVEN MATERIAL, THAT IS CORRECT. I HAD  
10 PLENTY OF TIME, IN MY OPINION, TO COME UP WITH A GOOD  
11 ASSESSMENT OF THIS CASE FOR PURPOSES OF COURT TESTIMONY.



12 Q. AS TO NO. 1, DID YOU ASK FOR ANY MORE MATERIAL?  
13 A. NO.  
14 Q. IN CASES LIKE THIS, GENERALLY, ARE YOU AWARE THAT  
15 BESIDES PEOPLE LIKE DR. HAMMAR, WHO HAVE BEEN RETAINED BY  
16 MS. CHABER, THERE MIGHT BE SOME OTHER PEOPLE WHO ALSO LOOKED  
17 AT THE CASE AND, FOR EXAMPLE, LOOKED AT IT AT THE REQUEST OF  
18 DEFENDANTS?  
19 A. WELL, WHEN YOU SAY "CASES LIKE THIS," COUNSEL, I  
20 HAVE NOT SEEN OR BEEN INVOLVED WITH A LUNG CANCER CASE LIKE  
21 THIS THAT HAS BEEN CONTESTED.  
22 Q. JUST GENERAL CASES.  
23 A. YOU SAID "CASES LIKE THIS," COUNSEL, AND THIS IS  
24 MY FIRST TIME THAT I HAVE TESTIFIED IN --  
25 THE COURT: DON'T ARGUE WITH HIM. HE CHANGED  
26 THE QUESTION.  
27 MR. BARRON: I DIDN'T MEAN SPECIFICALLY A LUNG  
28 CANCER. LET ME JUST START OVER.

JUDITH ANN OSSA, CSR NO. 2310

0052

1 Q. IN CASES WHERE YOU ARE BEING RETAINED BY  
2 MS. CHABER, AS YOU HAVE IN THE PAST, YOU ARE ALWAYS AWARE,  
3 AREN'T YOU, THAT THERE IS A DEFENDANT, AND THAT DEFENDANT  
4 OFTEN WANTS TO GET A SECOND OPINION OR RETAIN SOMEBODY TO  
5 LOOK AT IT TO SEE WHETHER IT MAKES SENSE FROM THEIR POINT OF  
6 VIEW; CORRECT?  
7 A. CORRECT.  
8 Q. AND SOMETIMES, THERE ARE DEPOSITIONS --  
9 A. CORRECT.  
10 Q. -- OF THOSE PEOPLE ON THE DEFENSE SIDE WHO HAVE  
11 LOOKED AT IT?  
12 A. CORRECT.  
13 Q. DID YOU ASK FOR ANY OF THOSE DEPOSITIONS TO TRY  
14 TO FIGURE OUT WHETHER NO. 1 SHOULD BE WRITTEN AS IT WAS  
15 WRITTEN?  
16 A. WELL, FIRSTLY, I DID NOT ASK FOR THOSE  
17 DEPOSITIONS, BUT NO. 1 SHOULD BE WRITTEN AS IT IS WRITTEN.  
18 IN ANY CASE, I THINK IT'S VERY CLEAR WHAT I DID  
19 AND WHY I DID IT.  
20 Q. DO YOU KNOW WHO DR. WYNDER IS, W-Y-N-D-E-R?  
21 A. I KNOW OF A DR. WYNDER WHO HAS PUBLISHED STUDIES  
22 THAT RELATE TO DIET AND CANCER.  
23 Q. RELATING TO WHAT?  
24 A. DIET AND CANCER IN PARTICULAR. HE HAS ALSO DONE  
25 SOME SMOKING STUDIES.  
26 Q. DO YOU KNOW AN ERNEST WYNDER?  
27 A. NOT PERSONALLY, BUT I KNOW I'VE READ ARTICLES.  
28 Q. DO YOU CONSIDER THOSE ARTICLES RELIABLE

JUDITH ANN OSSA, CSR NO. 2310

0053

1 AUTHORITIES?  
2 A. I NEED TO LOOK AT THEM ONE BY ONE.  
3 Q. YOU'RE NOT FAMILIAR ENOUGH WITH DR. WYNDER AND  
4 HIS REPUTATION IN THE FIELD TO THINK THAT WHAT HE HAS  
5 PUBLISHED IS RELIABLE UNLESS YOU LOOK AT THEM ONE BY ONE?  
6 A. THAT IS CORRECT. I NEVER SAID THAT OF ANY  
7 AUTHOR. I'D WANT TO LOOK AT EACH ARTICLE OVER THE YEARS OF  
8 ALL OF US. OVER THE YEARS, ALL OF US AT TIMES WRITE  
9 ARTICLES THAT WE MAY LATER CHANGE OUR VIEWS ON.  
10 Q. YOU MADE A STATEMENT THAT: "THE RELATIONSHIP  
11 BETWEEN SMOKING AND LUNG CANCER IS VERY STRONG.  
12 IN FACT, IT HAS BEEN CONSISTENTLY SHOWN FROM  
13 COUNTRY TO COUNTRY WORLDWIDE."  
14 DO YOU REMEMBER SAYING THAT --

15 A. YES.  
16 Q. -- THIS MORNING?  
17 A. PROBABLY. I HAVE SAID THAT STATEMENT BEFORE.  
18 I'M NOT CERTAIN IF IT'S TODAY.  
19 Q. IT WAS TODAY, BECAUSE AT THE LUNCH BREAK, I ASKED  
20 OUR COURT REPORTER TO GET IT VERBATIM, SO I WOULDN'T MAKE A  
21 MISTAKE.  
22 ARE YOU AWARE OF AN ARTICLE BY ERNEST WYNDER  
23 ENTITLED "COMPARATIVE EPIDEMIOLOGY OF CANCER BETWEEN THE  
24 UNITED STATES AND JAPAN"?  
25 A. NO, I DON'T RECALL THAT ARTICLE.  
26 MR. BARRON: MAY I SHOW IT TO YOU. I'LL HAVE  
27 THIS MARKED.  
28 THE CLERK: DEFENDANT'S EXHIBIT 2800.  
JUDITH ANN OSSA, CSR NO. 2310

0054

1 (DOCUMENT MORE PARTICULARLY  
2 DESCRIBED IN THE INDEX MARKED  
3 FOR IDENTIFICATION DEFENDANT'S  
4 EXHIBIT # 2800)  
5 MR. BARRON: THIS ONE IS FOR HIS HONOR.  
6 Q. ARE YOU FAMILIAR WITH THAT?  
7 A. I HAVE NOT READ IT BEFORE.  
8 Q. OKAY. THE RULE IS, I CAN'T ASK YOU ABOUT IT  
9 THEN, SO CAN I TAKE IT BACK.  
10 ARE YOU AWARE OF STATISTICS SHOWING THE  
11 PERCENTAGE OF MEN IN JAPAN WHO SMOKE AS OPPOSED TO THE  
12 PERCENTAGE OF MEN IN THE UNITED STATES WHO SMOKE?  
13 A. NOT OFF THE TOP OF MY HEAD.  
14 NOW, I'M AWARE OF JAPANESE STUDIES OF LUNG CANCER  
15 THAT HAVE BEEN LINKED TO SMOKING, BUT I DON'T RECALL THE  
16 NUMERIC PROPORTIONS OF SMOKERS FOUND IN THOSE STUDIES.  
17 Q. YOU DON'T KNOW WHETHER THE JAPANESE MEN SMOKE TO  
18 A MUCH GREATER PERCENTAGE THAN AMERICAN MEN?  
19 A. YOU MEAN THE PROPORTION WHO SMOKE?  
20 NO, I DON'T OFFHAND. AT TIMES, THE PROPORTION  
21 HAS BEEN VERY HIGH IN THE U.S. OF COURSE, IT HAS BEEN  
22 DROPPING MARKEDLY.  
23 AND IN JAPAN, AT ONE POINT IT WAS VERY LOW. IT  
24 DID INCREASE MARKEDLY. WHAT THE COMPARISONS ARE NOW OR  
25 EARLIER, I DON'T HAVE THOSE NUMBERS IN MY HEAD.  
26 Q. ARE YOU AWARE THAT AS LONG AS -- LET ME ASK YOU,  
27 EVEN MORE THAN 30 YEARS AGO, IN 1955, ARE YOU AWARE WHETHER  
28 THE JAPANESE MEN SMOKED AT A MUCH HIGHER PERCENTAGE THAN THE  
JUDITH ANN OSSA, CSR NO. 2310

0055

1 UNITED STATES MEN?  
2 A. I'M NOT AWARE OF THAT, NO.  
3 Q. ARE YOU AWARE OF WHETHER THERE'S ANY DISPARITY --  
4 DO YOU WANT TO STOP?  
5 A. I DID WANT TO SAY AT CERTAIN POINTS IN TIME,  
6 AROUND ABOUT 85 TO 90 PERCENT OF MEN IN INDUSTRIAL SETTINGS  
7 IN THE U.S., FOR EXAMPLE, HAD SMOKED, AND YOU CAN'T GET MUCH  
8 HIGHER THAN THAT.  
9 AT CERTAIN POINTS IN TIME, JAPANESE SMOKING RATES  
10 ARE LOWER. THEY COULD WELL, AS I INDICATED, HAVE BEEN  
11 HIGHER AT OTHER PERIODS.  
12 Q. DO YOU HAVE AN IDEA WHAT THE ADJUSTED LUNG CANCER  
13 RATE, CANCER MORTALITY RATE IS FOR JAPANESE MEN IN THE  
14 DECADE OF 1985 WHEN COMPARED WITH U.S. MEN?  
15 A. I DON'T HAVE THOSE NUMBERS, NO.  
16 Q. JUST A COUPLE MORE QUESTIONS -- WELL, MORE THAN A  
17 COUPLE, BUT I'M GETTING CLOSE.

18 DO YOU AGREE THAT EPIDEMIOLOGY IS THE STUDY OF  
19 POPULATION GROUPS?  
20 A. IT INCLUDES THAT. THAT'S NOT ITS DEFINITION.  
21 Q. DO YOU AGREE THAT, GENERALLY, WHAT YOU'RE TRYING  
22 TO DO IS TO COMPARE HOW FREQUENTLY DISEASE OCCURS IN ONE  
23 GROUP COMPARED WITH ANOTHER GROUP?  
24 A. THAT'S ONE PART OF WHAT WE DO.  
25 Q. DO YOU AGREE THAT IT DOES EMPLOY STATISTICAL  
26 METHODS?  
27 A. WE USE STATISTICAL METHODS, YES.  
28 Q. AND DO YOU AGREE THAT IT MEASURES THE STRENGTH OF  
JUDITH ANN OSSA, CSR NO. 2310

0056

1 THE ASSOCIATION BETWEEN AN AGENT AND DISEASE AMONG OTHER  
2 THINGS, SO-CALLED RELATIVE RISK?  
3 A. IT IS.  
4 Q. DO YOU AGREE THAT STATISTICAL METHODS CANNOT  
5 ESTABLISH PROOF OF A CAUSAL RELATIONSHIP?  
6 A. NOT ON THEIR OWN.  
7 Q. AND SO IN THAT REGARD, YOU AGREE WITH THE SURGEON  
8 GENERAL; CORRECT?  
9 A. I DON'T KNOW. I DON'T RECALL ALL THE MANY  
10 STATEMENTS MADE BY THE SURGEON GENERAL.  
11 Q. DO YOU AGREE THAT CAUSATION THEN BECOMES A MATTER  
12 OF JUDGMENT?  
13 A. IT INCLUDES JUDGMENT, OF COURSE.  
14 Q. AND THE JUDGMENT IS TO JUDGE THE SIGNIFICANCE OF  
15 THE ASSOCIATION THROUGH VARIOUS CRITERIA; CORRECT?  
16 A. NO, THAT'S NOT THE WORD. I'D GO AND COMPLETE THE  
17 LIST OF CRITERIA AND EXPLAIN EACH ONE OF THEM. IT'S NOT  
18 TRITE LIKE THAT, COUNSEL.  
19 Q. NOW, I KNOW THAT YOU WOULD GO INTO THE DEPTH OF  
20 IT, BUT THAT IS WHAT YOU DID?  
21 A. I WOULDN'T CHARACTERIZE IT THAT WAY.  
22 Q. NOW, ARE YOU SUGGESTING THAT IT'S PROPER FOR YOU  
23 TO ESTABLISH OR PROVE A CAUSE OF DISEASE IN A PARTICULAR  
24 INDIVIDUAL BY REFERENCING WHAT THE EPIDEMIOLOGICAL STUDIES  
25 SHOW?  
26 A. ABSOLUTELY. THE EPIDEMIOLOGICAL STUDIES PROVIDE  
27 THE HUMAN EVIDENCE, UNDERPINNINGS FOR INFERRING CAUSE IN  
28 HUMANS.

JUDITH ANN OSSA, CSR NO. 2310

0057

1 NOW, OBVIOUSLY, YOU ALSO NEED EVIDENCE OF  
2 EXPOSURE, YOU NEED A DIAGNOSIS AND OTHER PARTS.  
3 BUT NEVERTHELESS, HUMAN EVIDENCE COMES FROM  
4 GROUPS OF PATIENTS, NOT JUST ONE PATIENT, AND GROUPS OF  
5 PEOPLE. AND SO IT'S ESSENTIALLY EPIDEMIOLOGIC IN NATURE.  
6 Q. YOU AGREE THAT, IN FACT, WHAT YOU SUGGEST IS THE  
7 PROCESS IS NOT FOR WHICH THE PROCESS WAS DESIGNED?  
8 A. I DON'T UNDERSTAND THE QUESTION.  
9 Q. DO YOU AGREE THAT THESE STATISTICAL METHODS AND  
10 THE OTHER FEATURES OF EPIDEMIOLOGY WERE NOT DESIGNED TO  
11 PROVE OR ESTABLISH CAUSE IN A PARTICULAR INDIVIDUAL?  
12 A. I DON'T UNDERSTAND THE QUESTION. I'VE INDICATED  
13 EPIDEMIOLOGY IS ABOUT DETERMINING CAUSE IN GROUPS OF  
14 PEOPLE.  
15 IF YOU THEN WISH TO MAKE INFERENCES ABOUT  
16 INDIVIDUALS, YOU HAVE TO USE THAT INFORMATION.  
17 NOW, THE PRIMARY DESIGN OF WHAT WE DO IS ALWAYS  
18 WE LOOK AT GROUPS TO REACH AN INFERENCE ABOUT INDIVIDUALS.  
19 SO IT IS TRUE THAT OUR PRIMARY FOCUS IN THIS  
20 EXERCISE IS STUDYING GROUPS.

21 AND SINCE WE'RE IN THIS AREA, A LOT OF OUR WORK  
22 FOCUSING ON MAJOR PUBLIC HEALTH DECISIONS IS INVOLVING A LOT  
23 OF PEOPLE, AND THEN A LOT OF THE USE OF IT IS ALSO FOR  
24 GROUPS.

25 BUT IT IS AT THE SAME TIME DESIGNED TO MAKE A  
26 CORRECT INTERPRETATION THAT RELATES TO THE INDIVIDUALS IN  
27 THE GROUPS TOO.

28 Q. HAVE YOU READ THE SURGEON GENERAL'S REPORT  
JUDITH ANN OSSA, CSR NO. 2310

0058

1 DEALING WITH THAT VERY ISSUE I JUST ASKED YOU ABOUT?

2 I'D LIKE TO SHOW YOU PAGE --

3 MS. CHABER: WHAT YEAR?

4 MR. BARRON: 1964.

5 THE WITNESS: ONCE UPON A TIME, I THINK I READ  
6 MOST OF THAT REPORT.

7 MR. BARRON: Q. DOCTOR, IF YOU HAD WANTED TO  
8 SECURE SOME MORE INFORMATION FROM MS. CHABER BEFORE COMING  
9 TO COURT AND WRITING 1, 2, 3, 4, WOULD YOU HAVE FELT THAT  
10 YOU WOULD HAVE BEEN ABLE TO ASK FOR THAT INFORMATION?

11 A. I DON'T QUITE UNDERSTAND. I DIDN'T NEED TO ASK  
12 FOR ANYTHING MORE IN ORDER TO STATE WHAT I'VE STATED TODAY  
13 AND REACHED THE OPINIONS I HAVE REACHED IN THIS TRIAL.

14 MR. BARRON: I HAVE NO FURTHER QUESTIONS AT THIS  
15 TIME. THANKS.

16 THE COURT: ANYTHING FURTHER?

17 MS. CHABER: NO.

18 THE COURT: OKAY. MAY DR. SMITH BE EXCUSED?

19 MS. CHABER: YES.

20 THE COURT: MR. BARRON, MAY DR. SMITH BE  
21 EXCUSED?

22 MR. BARRON: YES. CERTAINLY, YOUR HONOR.

23 THE COURT: DR. SMITH, YOU ARE EXCUSED.

24 (WITNESS EXCUSED)

25

26

27

28

JUDITH ANN OSSA, CSR NO. 2310